前往化源商城

83-43-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:ATP-dependent translocase ABCB1
External ID: CHEMBL2077853
Protocol: N/A
Comment: Journal: Biol. Pharm. Bull.
Year: 2002
Volume: 25
Issue: 1
First Page: 393
Last Page: 396
DOI: 10.1248/bpb.25.393

Target ChEMBL ID: CHEMBL4302
ChEMBL Target Name: P-glycoprotein 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeActivity Comment
Activitysubstrate [+]
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR985
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.5265-7.1483-6.3353-8.6464-2.6851-3.55893.2191-3.1242-5.8134-5.6348-5.47660.4473-0.0628-2.5265QC'd by SIGMAInactive0-4.274510.6363
Inactive00043.9024-0.01911.091.23652.36520.00372.0670.4851-0.4224-1.0393-0.4413.17850.34623.9024QC'd by SigmaAldrichInactive0
Inactive00040.8889-4.98190.1870.7854-0.1677-2.0871-0.80150.24410.7043-8.80280.1379-2.37921.85830.8889QC'd by ChemServiceInactive0-7.06644.95490.4482
Inhibitor50.390553.327221Partial curve; partial efficacy-4.29773.06540.9802-53.3433-0.0161-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8509-1.3968-0.7491.0621-2.87011.05283.12180.0760.9249-0.49840.7261-1.3704-19.9808-46.8509QC'd by SigmaAldrichInactive0
Inhibitor70.827737.733910Partial curve; partial efficacy; poor fit-4.14981.46410.7102-39.7339-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.77821.0091-5.79512.7551.2254-6.9293.33021.728-8.1392-0.7165-6.4259-8.7096-8.3826-29.7782QC'd by SigmaAldrichInhibitor70.827741.854910Single point of activity-4.14984.50450.8302
Inhibitor61.503849.916621Partial curve; partial efficacy-4.21113.1320.892-53.3018-3.3852-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.2741-8.1807-7.61190.23321.57810.17121.3858-3.7535-3.206-6.6036-4.2950.0288-15.3692-42.2741QC'd by SIGMAInactive0
Inhibitor52.384150.532421Partial curve; partial efficacy-4.28082.40640.9534-51.6847-1.1523-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.2915-0.3854-0.06330.2042-1.816-8.719-1.02010.9052-1.1643-1.4537-2.6853-2.4432-20.0028-40.2915QC'd by SIGMAInhibitor58.775939.524221Partial curve; partial efficacy-4.230810.8135
Inactive0004-9.709-4.4881-6.0445-8.8766-4.0388-0.5862-4.6549-8.3113-5.6134-4.8338-4.5642-0.5579-3.4555-9.709QC'd by Alfa AesarInactive0-4.15283.990.694
Inactive00041.66471.2462-0.14863.91093.85360.66890.332-0.85721.14780.26430.82850.06271.34331.6647QC'd by SV ChembiotechInactive0-4.16373.92950.6564
Inactive0-6.2164.95490.70982-6.490740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5913-5.6041-9.9923-0.3428-7.6059-8.1832-4.6842-7.94470.1162.2630.2481.13570.77486.5913QC'd by SigmaAldrichInactive0
Inactive0-4.16644.95490.6737-25.7581-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.0484-0.84940.9603-8.21540.11392.05482.69681.41610.7927-9.70141.13732.2368-2.4398-21.0484QC'd by ChemServiceInactive0-4.36642.33320.8792
Inactive0-8.56773.1320.69960.5-9.217540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1871-8.0979-1.72310.81240.29791.59360.956-0.5761.2867-4.1414-0.48432.01310.0104-0.1871QC'd by SIGMAInactive0
Inactive00045.07940.37572.19050.57630.92270.78453.46994.04961.90151.38273.96340.9117-0.60225.0794QC'd by SIGMAInactive0-4.96862.40640.6273
Inactive0-6.16074.95490.57915.5-2.430540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1812-3.6421-0.044-0.36213.4152-5.3209-0.5383-7.85872.63685.21583.6992.344410.63857.1812QC'd by City ChemicalInhibitor54.870797.99941Partial curve; high efficacy-4.26071.78850.9628
Inactive0004-7.623-2.2142-5.4178-2.8594-1.2478-3.2961-1.8162-3.3949-3.2651-2.4468-13.60120.62040.0323-7.623QC'd by SIGMAInactive0
Inactive0-7.13754.0950.34570-4.700140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.0759-3.7616-3.6914-6.6307-6.3734-2.2758-1.4469-2.07440.5601-2.1426-0.4933-0.57645.1155-1.0759QC'd by SIGMAInactive0-4.58753.29750.926
Inactive0-6.92270.30.66969.5-12.317940 0 0 0 0 0 0 0 0 0 0 0 0 0 010.1368-8.154-8.9165-0.0326-1.7004-6.75864.0282-0.75942.5751-1.1314-0.72269.25986.41410.1368QC'd by SIGMAActivator26.751674.08270Partial curve; high efficacy-4.57272.18760.9777
Inactive0-8.31644.95490.36241-4.006940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.262-4.04751.1113-0.82860.46322.60630.59311.42180.5483-1.23861.81471.70282.46480.262QC'd by SIGMAInactive0-8.81644.95490.6203
Inactive0-4.86070.50.827124-3.343540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.3215-3.1196-2.8382-4.3087-0.9342-1.40680.1964-2.25525.21846.34245.162110.173116.8440.3215QC'd by LKT LabActivator9.757633.8970Complete curve; partial efficacy-5.01073.06540.9367
Inactive0-7.82850.70.757422.5-441 0 0 0 0 0 0 0 0 0 0 0 0 0 13.832412.68164.022614.57444.428120.650914.83922.328422.246920.362223.860820.325322.23313.8324QC'd by SIGMAInactive0-4.42850.80.8451
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR504
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator0.769618.541110Partial curve; partial efficacy; poor fit-6.11370.40.4771201.45892.40 0 0 0 0 0 0 0 0 0 1 1 1 1 18.43542.60297.16556.98426.77576.23584.39893.727414.10836.104412.34916.28710.24048.4354QC'd by SIGMAInactive0-7.46371.10.4107
Activator0.001518.544Complete curve; partial efficacy-8.81374.95490.845716.5-21.20 0 0 0 0 0 0 0 0 0 0 1 0 1 112.76338.520316.029918.960814.610214.569714.66815.484519.340417.405215.435716.74874.776812.7633QC'd by AcrosInactive0
Inactive040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.4538.53828.60629.13179.549110.755911.43756.467911.275510.13049.21297.3275-0.1191-11.453QC'd by SIGMAInactive0-4.36422.40640.8668
Inactive000417.43489.84064.73143.893717.43064.73392.71741.799421.142216.61518.79213.32233.134217.4348QC'd by Sigma DiscoveryCPRInactive0
Inactive000417.41599.11946.7603-2.39424.5125-5.07691.71712.688120.52570.113721.134-0.09350.75717.4159QC'd by EnamineInactive0-4.46372.35310.6137
Inactive0-8.51372.40640.34146.5-2.869340 0 0 0 0 0 0 0 0 0 0 0 0 0 09.2286-0.79294.86514.6489.82256.79684.62743.882111.065210.47076.49230.8715-0.7419.2286QC'd by SIGMAInactive0
Inhibitor3.063824.51160Complete curve; partial efficacy; poor fit-5.51374.95490.4049-18.61465.897-1.40 0 0 1 1 0 0 0 0 0 0 0 0 0 0-11.6821-3.038721.1044-20.78423.7169-18.207310.98469.041514.7886-15.2892-21.1562-17.0848-22.0042-11.6821QC'd by SIGMAInactive0
Activator0.001935.242610Complete curve; partial efficacy; poor fit-8.71424.95490.546629.4733-5.76921.40 0 0 0 0 0 0 0 0 0 0 1 1 1 1-35.059810.398831.296228.151536.89384.846829.689133.269131.780835.498622.02484.7913-29.1164-35.0598QC'd by SIGMAInactive0-4.31423.51170.6226
Inactive0004-0.31614.47693.98640.77972.2321.48744.16990.43690.07470.80680.3965-3.2133-3.9851-0.3161QC'd by SIGMAInactive0-4.71374.95490.3304
Inhibitor54.482733.50530Partial curve; high efficacy-4.26373.92950.9608-34.0053-0.5-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.00440.50840.4104-0.8948-3.2842-0.42840.0932-3.308-1.82040.56451.2561.479-9.8714-30.0044QC'd by Sigma DiscoveryCPRInhibitor68.589649.00410Single point of activity-4.16374.50450.9035
Inactive0-6.31374.95490.40220.5-2.854340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9062-1.42020.2852-3.8028-4.0452-3.8452-3.7145-3.80550.63741.33431.7137-3.28390.5803-2.9062QC'd by MP BiomedicalsInactive0
Inhibitor61.130658.88120Partial curve; high efficacy-4.21373.19250.9781-59.7265-0.8453-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-47.5201-0.605-1.4306-2.7189-0.8465-0.0963-1.1087-1.55290.5068-0.225-0.0391-7.585-12.7325-47.5201QC'd by SIGMAInhibitor61.130669.99940Partial curve; partial efficacy-4.21373.990.9846
Inhibitor48.508455.41370Partial curve; high efficacy-4.31423.06540.992-53.97671.437-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.95211.59250.5164-0.94190.64010.73652.10781.92572.71730.23973.6782-1.5898-20.1662-46.9521QC'd by SIGMAInhibitor54.427380.68770Partial curve; high efficacy-4.26422.47290.9773
Inactive00041.1920.359-0.3975-0.251.0086-0.1111.15210.61861.1885-1.45780.6853-0.92120.6021.192QC'd by SIGMAInactive0
Inactive00040.2182-3.0991-1.93151.3572-2.42631.55190.1835-0.68480.605-0.3437-2.1085-0.74640.05991.72430.2182QC'd by LightBiologicalsInactive0
Activator68.589630.210110Single point of activity-4.16373.24750.923330-0.210130 0 0 0 0 0 0 0 0 0 0 0 0 0 021.8495-0.3001-1.0271-2.0701-0.01770.97450.4274-1.8475-0.9875-0.00953.49112.8063.96521.8495QC'd by SIGMAInactive0-4.46371.92820.7837
Activator17.228923.958720Partial curve; partial efficacy-4.76370.60.7544240.04132.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.99880.30040.8704-1.63220.2766.3859-0.80141.77834.025210.31816.43328.494618.8419-1.9988QC'd by LightBiologicalsActivator24.336535.974310Single point of activity-4.61374.0950.8673
Inactive00040.8624-0.4215-2.3373-2.43560.2408-1.76690.8666-1.7395-2.0022-1.4521-1.4395-0.981-0.53890.8624QC'd by LightBiologicalsInactive0-4.51374.95490.8869
Inactive0-4.11374.95490.654990.039740 0 0 0 0 0 0 0 0 0 0 0 0 0 06.5998-0.8326-1.8287-1.08391.30271.03891.22330.81780.8549-1.37240.03750.73910.19056.5998QC'd by SIGMAInactive0-4.56374.95490.8448
Inactive0-4.56374.50450.4774.5-1.13740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.7168-1.8447-2.9517-3.0308-1.8846-0.48982.2361-1.7012-0.2024-2.7129-0.6292-0.32113.7485-3.7168QC'd by SIGMAInactive0-4.11374.95490.7344
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR163
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00043.0633-0.75412.1391.5904-0.3839-1.1415-0.39720.3007-0.97562.17540.8962-0.70775.67143.0633QC'd by ACCInactive0-4.475110.3403
Inactive0-4.47512.58840.5668.5-0.350840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.86480.1037-0.8896-0.4598-1.86570.62930.11860.461.3225-4.0423-0.7584-0.26931.61755.8648QC'd by ACCInactive0-4.87510.96410.6959
Inconclusive26.603243.928410Partial curve; high efficacy-4.57511.75290.950842-1.92842.10 0 0 0 0 0 0 0 0 0 0 0 0 0 032.0411-4.94030.1803-1.7907-1.04840.7187-2.0655-1.6464-0.9268-3.163-1.69577.805612.275332.0411QC'd by ACCInconclusive14.960143.862810Partial curve; partial efficacy-4.82511.96730.9669
Inactive0-4.77511.17050.46487-2.090540 0 0 0 0 0 0 0 0 0 0 0 0 0 05.8087-2.6379-0.128-0.3535-5.64580.03570.6444-4.5926-6.7421-1.9435-0.94861.98431.17355.8087QC'd by ACCInactive0-9.12514.95490.3263
Inactive00041.42561.18570.65356.04820.39286.34775.07265.4272.92610.04150.34843.0231-0.03451.4256QC'd by RTIInactive0
Inactive0004-1.88582.35057.09190.33143.3965-1.34684.203-0.8178-0.3747-1.06299.6715-2.4181-0.776-1.8858QC'd by RTIInactive0
Inactive0410.19018.95610.325512.63911.810913.69999.62495.66968.687812.306313.512815.91738.562510.1901QC'd by RTIInactive0
Inactive0004-0.41364.053-1.44611.85171.21114.06523.09290.81280.93140.5931-2.12422.4304-0.681-0.4136QC'd by RTIInactive0
Inactive00040.842-0.47542.86752.25690.4215-1.5297-2.07673.62060.9619-1.5025.02941.288-1.44990.842QC'd by RTIInactive0
Inconclusive0.00215.510Complete curve; partial efficacy; poor fit-8.70534.50450.795614-1.51.40 0 0 0 0 0 0 0 0 0 0 1 1 0 1-9.16440.693913.915611.436716.139211.324915.416415.994911.157614.795712.415311.295913.1797-9.1644QC'd by RTIInactive0-4.10534.95490.806
Inactive0004-6.75480.2459-1.60532.34130.73913.9972-1.3651-1.7233-3.4099-1.711.5906-2.29334.2594-6.7548QC'd by RTICytotoxic74.351433.63620Partial curve; partial efficacy; poor fit-4.12874.0450.7048
Cytotoxic40.421673.990940Partial curve; high efficacy-4.39342.25260.9604-70.17013.8208-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.09312.03564.92412.49064.22714.26826.20750.1594-0.95685.63330.0103-1.2879-37.614-61.0931QC'd by RTICytotoxic50.887883.280741Partial curve; high efficacy-4.29342.40640.9709
Cytotoxic69.171880.051341Partial curve; high efficacy-4.16014.50450.9543-74.39445.6568-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.67343.72427.29138.5895.08398.48319.02366.00472.81232.47474.97363.2009-4.4556-62.6734QC'd by RTICytotoxic69.171870.875120Single point of activity-4.16014.95490.9592
Inactive00045.1373.18785.21485.1644.96454.2219-0.33642.43436.57815.74133.06254.20694.86615.137QC'd by RTIInactive0
Cytotoxic78.824137.545620Single point of activity-4.10334.95490.8973-36.54561-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.20472.52230.11410.250.7493-2.2911-0.3071-0.86864.6455-1.007-1.8243.89684.0876-29.2047QC'd by RTICytotoxic78.824134.719820Partial curve; partial efficacy; poor fit-4.10334.95490.8207
Cytotoxic54.894739.278640Partial curve; high efficacy-4.26053.1320.9761-38.27861-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.1488-1.31041.12321.8921-0.72281.240.11850.53022.330.65950.21212.9868-14.3497-33.1488QC'd by RTICytotoxic54.894761.362221Partial curve; partial efficacy-4.26052.18760.9745
Inactive00043.14233.21915.8769-1.7146-0.4681-0.26044.11687.43091.98552.08331.94551.2669-1.29783.1423QC'd by RTIInactive0
Inactive0004-2.77945.33392.168-2.2813-0.6736-2.0788-16.89162.24013.5698-1.00744.02973.9198-1.0474-2.7794QC'd by RTIInactive0-4.79590.40.487
Inactive0004-0.88360.18994.02715.7421-2.1210.15651.51726.95692.32841.27492.76063.93542.593-0.8836QC'd by RTIInactive0
Inactive0-6.964110.3333-0.776340 0 0 0 0 0 0 0 0 0 0 0 0 0 13.24412.13982.31925.45162.7289-2.13923.47190.2244-0.6655-1.88570.9391.8723-2.31343.2441QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:firefly luciferase
External ID: LUC790
Protocol: Tox21 Assay Protocol Summary:

3 ul of substrate mix (containing 50 mM Tris acetate, pH 7.6, 13.3 mM Mg acetate, 10uM D-luciferin, 10uM ATP, 0.01% Tween, 0.05% BSA and dH2O ) is dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS.) 1 uL of firefly luciferase mix (containing 50 mM Tris acetate, pH 7.6, 0.04 uM P. pyralis luciferase, 0.01% Tween, 0.05% BSA and dH2O) was then delivered by FRD to each well. Luciferase activity was then measured using a ViewLux CCD imager.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000074871 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000679832 uM-Replicate_1Activity at 0.0001616562 uM-Replicate_1Activity at 0.0003744726 uM-Replicate_1Activity at 0.0007728037 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00651 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.2010.90.8471131.115440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.54731.4227-0.0927-0.73721.51692.33370.74961.98550.53323.45031.33282.53683.90686.069.5473QC'd by LightBiologicalsActivator70.63415.92510Partial curve; partial efficacy; poor fit-4.1510.90.7402
Inactive00043.83132.48656.35684.00543.84138.25791.63143.11833.93691.19885.93977.44213.27273.8313QC'd by LightBiologicalsInactive0
Inhibitor27.540425.239720Partial curve; partial efficacy-4.563.06540.9464-24.23971-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.86643.54850.58071.273.5792-1.0506-0.74551.82640.64041.29330.55871.0439-10.0294-21.8664QC'd by LightBiologicalsInactive0-4.364.50450.8982
Inhibitor70.574761.494341Partial curve; high efficacy-4.15142.30310.9936-61.34170.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.84970.69220.24130.03541.62351.4902-0.6178-0.2576-0.1338-0.7741-1.5037-5.7105-17.9277-46.8497QC'd by LightBiologicalsInhibitor62.899858.392741Partial curve; high efficacy-4.20143.1320.9871
Inactive0-4.39890.90.710380.988440 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7160.31890.18581.95122.60040.67990.14231.73831.70660.79292.27513.9265.04871.716QC'd by LightBiologicalsInactive0
Inactive0004-1.2464-0.1277-3.31990.07610.0272-0.171-0.9426-1.275-0.8314-1.0122-0.1704-0.7926-0.2083-1.2464QC'd by LightBiologicalsInactive0
Inactive00049.0594-4.22375.94818.69258.92016.96137.5769-4.56141.7618.73328.6084-3.34-3.90129.0594QC'd by LightBiologicalsInactive0
Inactive00041.81981.5048-2.86521.29632.0381-3.75161.90181.93420.96122.92531.90792.69043.8991.8198QC'd by LightBiologicalsInactive0-4.19893.92950.4592
Inactive00041.0427-2.9040.2976-1.36752.4811.58460.60181.9111.8233-2.31412.7932-0.1252-3.80621.0427QC'd by LightBiologicalsInactive0
Inactive00041.81572.32444.23827.73370.21471.78012.640.32671.7625.77573.74973.61055.36231.8157QC'd by LightBiologicalsInactive0-4.51490.50.3892
Inhibitor89.358431.923510Single point of activity-4.04894.95490.9445-30.92351-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.10290.8105-1.44111.7887-0.1850.69522.96312.16590.03891.2506-0.78660.32282.6099-24.1029QC'd by LightBiologicalsInhibitor89.358427.433610Single point of activity-4.04894.95490.9335
Inactive0-6.39480.90.42680.05953.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.61711.84673.25183.75243.33334.00713.8712-0.9505-1.43963.0690.48362.44510.1858-1.6171QC'd by LightBiologicalsInactive0
Inactive00040.0907-0.4901-3.2387-0.7092-0.3212-0.94770.426-0.2568-0.3555-0.5594-0.8083-0.44290.5340.0907QC'd by LightBiologicalsInactive0
Inactive00040.8222.29930.05141.4340.8292-3.84692.04270.53252.7743.15713.841.89041.86440.822QC'd by LightBiologicalsInactive0
Inhibitor79.640758.055341Partial curve; high efficacy-4.09893.62720.9858-58.8675-0.8123-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.8693-1.39271.2532-1.8476-3.00891.0377-0.085-0.0864-1.0068-0.2868-1.8043-4.6859-9.7906-46.8693QC'd by LightBiologicalsInhibitor70.979924.628520Partial curve; partial efficacy-4.14893.57220.9379
Inactive0-4.04894.50450.8551-8.6034140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.33621.44610.98591.11170.77190.52781.33360.63411.98470.66550.3564-1.19960.4705-6.3362QC'd by LightBiologicalsInactive0-4.24891.46410.7616
Inhibitor31.705522.975520Partial curve; partial efficacy-4.49892.09370.9159-21.97551-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.22960.1079-1.25660.0804-0.4464-0.9265-0.24241.22035.1564-0.16970.1335-8.2794-14.2156-21.2296QC'd by SIGMAInhibitor39.914927.035120Partial curve; partial efficacy-4.39891.47870.9029
Inactive00041.68681.80593.04642.90412.6745-1.14845.3851.35853.20093.01323.66774.258211.12191.6868QC'd by SIGMAInactive0
Inactive0004-0.01532.91587.60184.7593.8923-5.03062.21774.13765.41963.00133.93875.23166.3628-0.0153QC'd by SIGMAInhibitor89.358418.599210Partial curve; partial efficacy; poor fit-4.04894.95490.8509
Inactive00043.7853-0.6681.31811.1372-0.42441.41111.52592.25831.1924-5.84795.2943-0.63157.19593.7853QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR541
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO, was added using a Flying Reagent Dispenser to generate a final concentration of 50 nM CITCO inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inhibitor3.349141.215910Single point of activity-5.47514.95490.5085-42.7363-1.5203-30 0 0 0 0 0 0 0 0 0 0 0 1 1 1-8.087121.89-8.6781-3.6855-6.25695.4433-2.2253-6.5947-10.7583-4.5705-16.1608-16.3686-5.5938-8.0871QC'd by ACCInactive0
Inhibitor2.660331.350422Complete curve; partial efficacy-5.57514.95490.7593-35.7832-4.4328-1.20 0 0 0 0 0 0 0 0 0 0 0 0 1 1-7.07487.0287-3.7117-8.93987.0191-8.6003-10.5811-9.6323-3.5772-9.7824-21.4714-32.0269-13.6825-7.0748QC'd by ACCInactive0
Inhibitor29.8493180.333140Partial curve; high efficacy-4.52511.86170.9403-183.9808-3.6476-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-139.3794-6.9891-4.5485-2.48725.72942.1105-4.4422-5.01950.98326.5263-18.8291-30.3545-53.8001-139.3794QC'd by ACCInhibitor29.8493162.790140Partial curve; high efficacy-4.52513.24750.9553
Inactive0-4.77512.40640.4777-19.93010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.4418-5.3665-6.0776-0.6378-0.7746-5.95928.056814.4063-4.2029-2.83313.6942-1.1786-14.0414-17.4418QC'd by ACCInactive0-4.57513.1320.6731
Inactive0-4.04014.95490.487724-5.718340 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6907-9.6058-16.8485-11.179-0.45450.0756-9.022-7.6078-4.898-2.6992-0.66814.3314-11.422917.6907QC'd by RTIActivator64.553243.03530Partial curve; partial efficacy-4.19013.92950.9117
Inactive0004-19.84863.3433-23.4364-34.1329-6.2414-5.0556-25.546-8.9103-6.9329-28.1976-6.81633.8592-42.036-19.8486QC'd by RTIActivator67.057937.01130Partial curve; partial efficacy; poor fit-4.17353.67720.7941
Inactive0-4.02734.95490.655322-3.294740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.0345-2.80161.8842-7.0081-1.7985-7.3345-5.4629-6.0156-0.7765-1.4972-8.9956-1.9725-7.487516.0345QC'd by RTIInactive0-4.27732.33320.6095
Inactive00047.8644-12.2433-5.1181-4.04961.28844.3493-4.5231-6.8637-4.8147-7.4445-2.1022-11.7632-20.07367.8644QC'd by RTIInactive0-4.37991.96730.5769
Inactive000412.77776.2553-5.7998-3.9544-6.27073.8508-4.3153-0.2911-4.79463.74813.8044.64191.374312.7777QC'd by RTIInactive0-4.28464.95490.3638
Inactive0-4.20534.44950.6434-17.42521.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.7713.79853.86442.4904-4.2833.78225.42352.6092-2.38-3.39182.70615.627-2.5037-15.771QC'd by RTIInactive0-5.20534.95490.321
Inhibitor5.9059106.654984Complete curve; high efficacy-5.228710.9844-102.49964.1553-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.8049.49943.6503-0.42471.07452.82466.38180.0721-15.1461-24.7454-55.3584-79.6141-94.3827-85.804QC'd by RTIInhibitor4.691398.416784Complete curve; high efficacy-5.32870.90.9674
Inactive0-4.69341.55790.702223-4.449740 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3595-2.1806-3.3591-6.2651-0.28090.121-6.0475-11.7066-7.89250.86856.2708-0.375526.069416.3595QC'd by RTIActivator71.880946.06290Single point of activity-4.14344.95490.7673
Inhibitor69.1718135.093943Partial curve; high efficacy-4.16013.06540.9789-149.2252-14.1313-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-117.8714-2.1311-17.2291-13.9078-13.6919-19.6465-13.3695-15.7919-17.4807-14.0473-10.7354-16.145-44.1916-117.8714QC'd by RTIInhibitor54.9451147.633342Partial curve; high efficacy-4.26012.40640.9628
Inactive0-6.14174.95490.4637-11.0778-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.73651.2389-2.2448-12.4683-0.62132.0757-1.40511.6174-8.0337-11.8106-11.9614-1.3448-17.9815-2.7365QC'd by RTIInactive0-4.34170.50.4602
Inhibitor8.844263.970182Complete curve; high efficacy-5.05331.46410.9355-69.4155-5.4454-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.4281-3.3461-7.3817-5.25411.5957-7.1494-6.1151-2.5632-12.7008-17.0044-40.829-49.2957-77.8583-59.4281QC'd by RTIInhibitor7.882431.683321Complete curve; partial efficacy-5.10332.33320.905
Inhibitor19.477457.938541Partial curve; partial efficacy-4.71051.34430.9334-57.56260.376-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-52.0338-12.41210.71942.24359.20663.0773-1.07773.1429-3.055-5.8935-11.5387-32.2284-42.404-52.0338QC'd by RTIInhibitor77.540938.538210Single point of activity-4.11054.95490.5991
Inactive0004-3.3574-9.0659-5.0523-7.9611.8345-6.6475-6.4054-4.0807-7.994-5.2589-4.8636-18.8381-16.5327-3.3574QC'd by RTIInactive0-5.70264.95490.3553
Inactive0-4.09594.95490.659231.5-0.506240 0 0 0 0 0 0 0 0 0 0 0 0 0 025.14185.9174-1.2243-9.58850.3121-2.79136.44825.5515-1.4762-0.4167-3.92814.3971-4.45225.1418QC'd by RTIActivator56.764849.34910Partial curve; partial efficacy-4.24591.80790.7545
Inactive000411.60064.5643-3.7194-10.097311.42282.41525.31161.6689-4.6133-3.7747-3.13611.8656-13.87311.6006QC'd by RTIInactive0-4.14513.29750.4562
Inactive0-4.06414.95490.569122-3.35640 0 0 0 0 0 0 0 0 0 0 0 0 0 016.3590.1187-1.3367-4.6228-5.1472-1.2162-0.1657-0.04880.0689-5.7723-5.23-1.7902-11.963316.359QC'd by RTIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CAR611
Protocol: Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells suspended in DMEM culture medium supplemented with 10% FBS, 5 ug/mL blasticidin, 0.5 mg/mL geneticin, 100 U/mL penicillin and 100 ug/mL streptomycin were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195, was added using a Flying Reagent Dispenser to generate a final concentration of 0.75 uM PK11195 inside each well. After a 24 hr incubation period at 37 C/5% CO2, four uL of ONE-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After a 30 min incubation period at room temperature, the luminescence intensity in the assay plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-2.36620.69570.44051.11090.5787-0.2699-0.32331.18450.0326-1.0092-1.73120.8267-2.1104-2.3662QC'd by SigmaAldrichInactive0
Inactive0004-0.2849-0.47850.10371.13040.3494-1.2942-2.3851-1.60740.1233-0.8459-1.8941-2.6451-0.2138-0.2849QC'd by SigmaAldrichInactive0
Activator53.984430.302520Partial curve; partial efficacy-4.26772.04370.980730-0.30252.20 0 0 0 0 0 0 0 0 0 0 0 0 0 022.9705-0.53970.19140.0778-0.1425-0.2776-1.9188-0.46281.1362-0.8514-0.42823.186710.348822.9705QC'd by SigmaAldrichActivator27.056334.152540Partial curve; high efficacy-4.56771.47810.9607
Inactive0-7.768610.69720.758810.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-1.08229.0278.56537.5724.21540.90080.24680.02675.66910.0433-7.0E-4-2.28440.3557-1.0822QC'd by SIGMAInactive0
Activator17.351737.620340Partial curve; high efficacy-4.76073.06540.989337.3935-0.22682.10 0 0 0 0 0 0 0 0 0 0 0 0 0 124.0027-1.13920.1686-0.1252-1.4390.2351-0.49480.65421.28420.05961.310721.815534.209324.0027QC'd by SIGMAActivator4.890445.728181Complete curve; high efficacy-5.31070.70.9547
Inactive00040.5220.023-1.1865-1.4762-0.05160.6407-0.0477-0.5943-1.0553-3.4872-1.7526-1.5011-0.45170.522QC'd by SIGMAInactive0-5.56914.95490.4552
Inactive0-4.27133.29750.65377-0.991840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.71270.1065-2.9589-3.3265-0.1367-0.53720.1194-0.7792-2.1668-3.2131-0.01280.58790.97235.7127QC'd by SigmaAldrichInactive0-4.12134.95490.6439
Inactive0004-4.945-2.5611-5.5604-5.5744-3.7841-2.51970.8205-4.2283-4.7634-6.5963-6.2633-3.1896-5.8718-4.945QC'd by SIGMAInactive0
Inactive0-4.16290.60.42327-1.160340 0 0 0 0 0 0 0 0 0 0 0 0 0 04.3597-0.362-3.0077-3.05030.2438-1.01930.3335-0.4699-1.28130.401-0.46414.3554-0.91184.3597QC'd by SIGMAInactive0-5.51292.33320.8433
Inactive0004-0.70380.0361-3.7089-1.7915-1.25830.16870.69770.1566-2.4696-3.4971-1.51-1.5395-3.4697-0.7038QC'd by SIGMAInactive0
Inactive0004-1.2777-1.6943-2.5955-3.5033-1.64891.17161.2363-2.1104-2.9787-3.3438-1.1157-1.1422-1.1735-1.2777QC'd by SIGMAInactive0
Inactive0004-0.56630.288-2.3707-2.7283-0.63382.07513.38390.0802-2.4707-3.83610.0879-0.2454-2.8389-0.5663QC'd by SIGMAInactive0-4.85851.88510.9504
Inactive0004-1.1005-0.9792-1.7954-2.6037-0.12-0.26040.3413-0.8959-1.9784-3.2297-1.6711-0.0062-3.6975-1.1005QC'd by SIGMAInactive0
Inactive0004-1.2459-4.784-9.0537-2.2125-3.0446-0.91621.9784-0.3992-6.2878-10.5833-9.5972-2.1042-10.227-1.2459QC'd by SIGMAInactive0
Inactive0004-1.0084-1.7104-1.9369-2.0369-1.6802-0.573-0.47480.085-2.3375-4.3727-2.4796-2.5942-2.7424-1.0084QC'd by SIGMAInactive0
Inactive0004-0.9643-2.3604-0.8724-2.1936-0.583-0.2670.1582-0.3325-2.7466-3.9462-1.2392-0.1393-2.9256-0.9643QC'd by SigmaAldrichInactive0
Inactive0004-6.2696-3.3484-4.8795-5.0177-4.9214-3.95680.8092-3.9748-5.0443-6.7588-5.093-3.1627-6.7773-6.2696QC'd by ChemServiceInactive0
Inactive0004-3.7787-1.21870.3496-1.1618-0.178-0.02990.1049-1.7277-1.4204-3.3075-1.8639-0.2976-4.4158-3.7787QC'd by SIGMAInactive0
Inactive0004-5.5543-3.7243-4.3348-6.0183-4.46860.85250.2555-1.1073-5.5639-6.2665-7.6529-4.829-7.4675-5.5543QC'd by SIGMAInactive0
Activator21.579778.216381Complete curve; high efficacy-4.6662.47290.975179.1210.90471.10 0 0 0 0 0 0 0 0 0 0 0 0 0 079.9059-0.6357-0.03330.1670.65420.84030.39860.65146.9793-1.6191.148938.519460.089479.9059QC'd by FisherActivator24.212873.718240Partial curve; high efficacy-4.6161.10.9797
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR224
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of PK11195 (final concentration = 0.75 uM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive00040.7001-2.07971.16113.0882-0.077102.1698.77392.9614-2.21710.116619.58354.13960.7001QC'd by ACCInactive0-4.52511.10.5248
Inactive00046.4354-1.02440.0097-0.0933-1.85581.1884-0.92732.35142.15013.76020.1771-1.03550.10946.4354QC'd by ACCInactive0
Inconclusive14.960164.783610Partial curve; high efficacy-4.82511.55790.966665.88741.10382.10 0 0 0 0 0 0 0 0 0 0 0 0 0 064.59921.6564-1.48951.3624-0.33672.53023.07761.2257-1.3673-1.46236.837225.336734.910764.5992QC'd by ACCInconclusive29.849380.826810Partial curve; high efficacy-4.52512.25260.8962
Inactive00047.00811.6498-1.43860.50060.40820.79470.89650.34840.35820.30331.35526.99592.91727.0081QC'd by ACCInactive0
Inactive00043.05635.54866.72620.53512.71380.70682.23040.2851-1.53215.16263.86991.54890.8433.0563QC'd by RTIInactive0
Inactive00040.74666.36313.94348.84614.56211.575.48974.19182.16295.86320.50451.34453.99310.7466QC'd by RTIInactive0
Inactive00040.67381.12332.28591.01811.5966-0.43621.77940.2945-1.37111.71640.89490.65662.50770.6738QC'd by RTIInactive0
Inactive00041.00343.59883.74021.61832.4828-24.1996-11.8417-15.26063.54570.8131-0.0321-11.9734-1.31061.0034QC'd by RTIInactive0
Inactive0-4.18464.95490.9125-10.752.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.31021.06850.91324.13362.67391.81972.26761.87431.57794.70882.78081.3363-11.4583-9.3102QC'd by RTIInactive0-3.83464.50450.8486
Inactive0-4.15534.95490.6213-8.5472540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.7063.03746.28947.39888.83679.30074.16635.48521.16012.64973.10975.62653.3473-6.706QC'd by RTIInactive0-4.50531.13410.921
Inactive0-4.07872.90230.7611-27.65215.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.71016.68477.71693.3955.081315.63232.80533.07480.28617.9345.15692.3389-1.44-19.7101QC'd by RTICytotoxic74.351457.123720Single point of activity-4.12872.90230.9124
Cytotoxic57.09755.000921Partial curve; partial efficacy-4.24343.57220.9446-54.11980.881-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.68171.44960.64610.87374.0413-0.6397-8.70514.50811.25313.61011.83811.5671-14.0711-46.6817QC'd by RTICytotoxic57.09772.527141Partial curve; partial efficacy-4.24342.35310.9803
Cytotoxic69.1718108.736442Partial curve; high efficacy-4.16012.63840.9717-107.06951.6669-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.11334.12134.26247.21762.32561.1447-8.56171.58873.20240.90921.8827-6.6983-25.0645-81.1133QC'd by RTICytotoxic54.9451118.001241Partial curve; high efficacy-4.26012.12110.9982
Inactive00041.23831.33150.88153.39274.07264.82921.16914.05412.98531.32630.32392.28032.47551.2383QC'd by RTIInactive0
Cytotoxic62.612238.428920Partial curve; partial efficacy; poor fit-4.20332.53340.9423-35.92892.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.44074.56793.2733.0004-0.82787.03151.32971.03340.94391.5864-0.53831.1816-10.0481-27.4407QC'd by RTICytotoxic55.803256.613421Partial curve; partial efficacy-4.25332.53340.9455
Cytotoxic34.636240.085420Partial curve; partial efficacy-4.46052.78680.9485-35.58544.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-37.55547.86573.08136.25493.50321.57814.64299.84995.08361.63343.0637-4.2032-21.4975-37.5554QC'd by RTICytotoxic48.92563.310741Partial curve; partial efficacy-4.31052.40640.966
Inactive0-4.95263.51170.4728-12.1793140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.88662.10451.60872.2705-1.9686-0.7779-1.63741.02741.49992.1762.5-23.0661-2.7817-0.8866QC'd by RTIInactive0-4.15262.63840.6052
Inactive0004-2.84033.5493.05938.34540.08545.4167-0.89290.03223.37180.29422.8684-1.08252.444-2.8403QC'd by RTIInactive0-4.09594.95490.8672
Inactive00040.57120.96791.09642.61560.08615.51343.14970.57852.83021.933.1832-1.67453.16860.5712QC'd by RTIInactive0
Inactive0-4.51414.95490.6339-9.2283240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.63681.3480.78612.61030.0177-0.69933.3843-0.57490.00933.38765.62053.6707-9.3569-0.6368QC'd by RTICytotoxic68.537737.040120Partial curve; partial efficacy; poor fit-4.16412.90230.9194
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: CAR404
Protocol: Tox21 Assay Protocol Summary:

A double-stable (hCAR and CYP2B6-2.2kb) transfected cell line, derived from human hepatoma (HepG2) cells, was utilized for the duration of the quantitative high-throughput screens. The HepG2-CYP2B6-hCAR cells were dispensed at 2500 cells/4 uL/well in 1536-well white solid bottom plates using a Multidrop Combi. After the assay plates were incubated at 37 C/5% CO2 for 4 hrs, 23 nL of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station. One uL of CITCO (final concentration = 50 nM) was added, using a Flying Reagent Dispenser, inside each well. After a 23 hr incubation period at 37 C/5% CO2, 1 uL of CellTiter-Fluor reagent was added into each well of the assay plates using a Flying Reagent Dispenser. The fluorescence intensity in the plates was then measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.264 uM-Replicate_1Activity at 8.390 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-1.2885-8.2133-8.16350-7.1502-6.0582-1.0685-6.9497-7.74221.4318-0.484-9.89-5.9739-1.2885QC'd by LightBiologicalsInactive0
Inactive0-4.21374.50450.3794-2.0019-11.536240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.2267-13.6359-11.5589-12.427-11.9862-12.3014-2.0849-11.776-12.2205-11.2807-10.5655-12.6043-10.0799-3.2267QC'd by SIGMAInactive0
Inactive0004-18.8355-16.5392-15.7843-14.6365-14.6435-14.8247-15.1826-17.2997-17.0567-15.571-15.4498-16.8771-18.7769-18.8355QC'd by SIGMAInactive0
Cytotoxic61.130668.499141Partial curve; partial efficacy-4.21373.57220.9855-82.6763-14.1772-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.8305-13.3313-15.7246-16.9851-15.1291-16.6431-12.0943-15.0603-13.2228-10.6311-12.392-15.5076-28.0786-69.8305QC'd by SIGMACytotoxic61.130688.918141Partial curve; high efficacy-4.21372.47290.9648
Inactive0004-9.4937-8.4802-2.4154-6.8019-7.6968-8.7013-4.9931-5.9136-8.161-5.4834-5.5854-7.8666-8.6242-9.4937QC'd by LightBiologicalsInactive0-8.06374.95490.5744
Inactive0-4.21373.29750.784-19.65540.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.54620.30110.54811.68972.3515-1.76286.6762-2.18030.3036-2.6294-0.6711-0.2348-3.468-15.5462QC'd by SIGMAInactive0-4.21370.40.6227
Inactive0004-0.8117-4.0669-9.8967-11.0574-6.4365-5.9282-6.3535-7.6972-5.2867-9.8338-1.3993-0.8947-7.6295-0.8117QC'd by SIGMAInactive0
Cytotoxic61.503855.678321Partial curve; partial efficacy-4.21113.990.9569-57.7149-2.0366-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.64770.26981.6175-2.9758-3.96481.7183-4.47090.3089-5.9715-1.9196-1.5152-1.5012-11.187-48.6477QC'd by ChemServiceInactive0-4.21114.95490.8972
Inactive0-4.11374.95490.6896-23.3009040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-17.75070.5104-1.55631.8378-3.19332.5092-0.693-8.08051.92620.04853.9244-2.18611.6782-17.7507QC'd by SIGMAInactive0-4.21374.0950.6638
Cytotoxic60.5715107.680742Partial curve; high efficacy-4.21771.86170.9797-127.4822-19.8016-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.5775-19.6657-16.6526-20.809-21.6607-19.7704-14.2217-18.8965-22.5975-21.7271-20.6249-34.5795-53.8367-96.5775QC'd by EPACytotoxic42.8813102.238741Partial curve; high efficacy-4.36771.96730.9874
Cytotoxic34.201550.561640Partial curve; partial efficacy-4.4661.46410.9284-54.0991-3.5375-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.0918-2.7848-1.0730.0864-3.1155-8.38860.2833-5.2666-5.937-8.2702-10.3681-18.193-25.3466-50.0918QC'd by CrescentCytotoxic30.482144.89120Partial curve; partial efficacy-4.5161.47810.9399
Inactive0-3.96370.80.6909-31.6-3.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23-4.3769-2.78840.141-3.552-4.8242-6.7976-4.9877-2.8309-6.1986-3.8792-6.6066-8.0591-23QC'd by Sigma DiscoveryCPRCytotoxic61.130637.500120Single point of activity-4.21373.62720.9475
Inactive00042.7896-2.2890.3967-3.4023-0.5931-3.73261.98680.266-0.04370.42130.10770.45910.0122.7896QC'd by SIGMAInactive0
Inactive00040.26690.57262.32333.2007-0.42921.18692.47032.29592.39542.45931.99820.27692.75730.2669QC'd by SIGMAInactive0
Inactive00040.15290.81242.78170.7373.17970.4171.1829-3.29880.4225-0.650.0220.90230.99470.1529QC'd by SIGMAInactive0
Inactive0-4.11374.95490.7475-10.5412240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11761.66523.16792.25360.69250.89822.26921.6541.01862.7189-0.12983.29222.2598-7.1176QC'd by SIGMAInactive0-4.56374.50450.3801
Inactive0004-3.2742-0.57391.18390.6992-0.1356-0.9956-3.9472-0.31020.02640.46931.55660.2082-3.8232-3.2742QC'd by SIGMAInactive0
Inactive0004-0.7927-6.5931-0.004-0.87430.5458-3.7497-2.0427-2.5866-3.6954-3.9867-18.7143-2.0222.5912-0.7927QC'd by SIGMAInactive0
Inactive0004-13.9982-8.8449-6.7122-3.2554-8.551-4.4661-2.4558-5.8647-10.1231-5.4289-3.8809-5.1227-8.4815-13.9982QC'd by SIGMAInactive0
Inactive0004-0.2549-3.2147-2.0568-1.3426-0.21941.32071.5504-1.1495-1.6104-0.5283-1.0103-2.0348-1.3745-0.2549QC'd by LightBiologicalsInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC875
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.3468-0.10070.0358-0.33470.23222.509-4.5860.2540.48071.16460.75384.1574-4.8525-0.3468QC'd by SIGMAInactive0
Inactive0004-3.3197-5.6995-7.8071-6.0662-4.9082-8.0484-7.708-4.8984-5.8365-2.5967-1.1821-5.7986-3.0963-3.3197QC'd by SigmaAldrichInactive0
Inactive00041.84520.97091.1435-0.24060.0731-0.12051.2062-0.18330.0921.20720.47061.31020.49521.8452QC'd by SIGMAInactive0-4.01730.70.5777
Inhibitor34.131725.96160Partial curve; partial efficacy-4.46682.33320.9617-25.96160-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.9681.69630.1516-1.09160.4925-0.73560.52772.66582.0E-4-2.8872-3.0257-4.5147-15.6179-24.968QC'd by SIGMAInhibitor48.212321.71050Partial curve; partial efficacy-4.31681.82650.8711
Inactive00041.39531.94521.30180.9104-0.31670.42261.07071.9713-0.37872.93970.83462.12710.21931.3953QC'd by SigmaAldrichInactive0
Inactive0-4.06334.95490.4301-7.0921-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.24341.0247-0.6334-0.0593-0.5529-0.870.3563-3.05990.0772-2.04451.2375-0.9179-0.0839-4.2434QC'd by SIGMAInactive0-4.31333.51170.5308
Inactive0-5.75854.95490.3744-2.0452140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.39762.44991.9442.7333-0.72910.18521.02430.39980.1524-5.0377-4.45790.10940.3382-0.3976QC'd by SigmaAldrichInactive0
Inactive00044.02841.30910.502-2.96730.6114-3.0343-5.43691.67780.79992.43120.8290.0491.04384.0284QC'd by Alfa AesarInactive0
Inactive0-5.26464.95490.4346-2.0801140 0 0 0 0 0 0 0 0 0 0 0 0 0 11.98340.29922.4906-0.22330.3752.7141.88570.4384-0.23811.8609-3.01220.5146-3.40011.9834QC'd by SIGMAInactive0
Inactive00042.63350.03471.26840.123-0.3218-0.7076-0.30731.1541.4491.46540.89010.0407-0.34962.6335QC'd by SIGMAInactive0
Inactive0-4.09724.95490.45685-0.300340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4899-1.55050.48970.6246-0.8749-0.70910.3983-0.38271.38450.1489-2.3336-0.5514-0.29293.4899QC'd by SigmaAldrichInactive0
Activator42.573923.761320Partial curve; partial efficacy-4.37091.46410.9148240.23872.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.55410.00531.42-0.16480.3750.50141.6438-0.125-0.76833.78914.61832.97299.933520.5541QC'd by SIGMAActivator60.13733020Partial curve; partial efficacy-4.22092.53340.9705
Inactive00042.55290.4063-0.01020.18952.3191-1.84951.7387-1.9418-1.54353.99270.02911.34360.7672.5529QC'd by SIGMAInactive0-8.36331.28760.3456
Inactive00041.41240.5842.30430.55631.00343.2421-0.03291.7832-2.03062.37860.03731.3846-0.48531.4124QC'd by ChemServiceInactive0
Inactive00043.2372-0.06260.30520.0902-0.17460.25520.3996-0.2881.25733.132-0.27620.86140.24633.2372QC'd by SIGMAInactive0
Inactive00042.54410.50790.20260.3539-0.13770.985-0.3504-1.23841.32581.2338-2.15810.15631.45512.5441QC'd by SIGMAInactive0
Inactive0-4.17223.67720.6648-5.8375140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-4.03120.75431.06750.67620.09292.30830.48760.50432.7882-0.24950.6636-0.05580.1164-4.0312QC'd by City ChemicalInactive0
Inhibitor17.334135.94590Complete curve; high efficacy-4.76113.1320.981-35.94590-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.7947-1.1822-0.3985-2.19492.5399-2.8881-1.15330.37421.44382.4728-1.8207-20.2287-32.2128-36.7947QC'd by InterchemInhibitor15.44939.10510Complete curve; high efficacy-4.81112.33320.9633
Inactive0-4.17994.0950.4925-4.84510.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.62090.76960.04541.12750.09010.13020.2945-0.00821.2284-0.19962.4956-2.29050.011-3.6209QC'd by SIGMAInhibitor46.785537.00050Partial curve; partial efficacy-4.32991.69240.9362
Inactive0004-3.6855-2.20722.44460.09531.2718-2.0196-1.5529-1.1351-0.9412-2.5691-0.9983-2.4138-2.9275-3.6855QC'd by SIGMAActivator5.431631.161281Complete curve; high efficacy-5.26511.34430.9707
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: TSHR942
Protocol: Tox21 Assay Protocol Summary:

TSHR-Hek293 cells were dispensed at 800 cells/4uL/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 18 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pin tool, followed by 1 ul medium containing Ro20-1724. The plates were incubated at room temperature for 30 min. 2.5 ul/well of cAMP-d2 and 2.5ul/well of anti-cAMP-cryptate was added respectively into the assay plates using a Flying Reagent Dispenser. After 1 hr incubation at room temperature, the fluorescence intensity in the plates was measured using an Envision plate reader. Each test compound was measured at 15 concentrations and in triplicates.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W615-Activity_Score-Replicate_1W615-Curve_Description-Replicate_1W615-Fit_LogAC50-Replicate_1W615-Fit_HillSlope-Replicate_1W615-Fit_R2-Replicate_1W615-Fit_InfiniteActivity-Replicate_1W615-Fit_ZeroActivity-Replicate_1W615-Fit_CurveClass-Replicate_1W615-Excluded_Points-Replicate_1W615-Max_Response-Replicate_1W615-Activity at 0.0000060039 uM-Replicate_1W615-Activity at 0.0000137707 uM-Replicate_1W615-Activity at 0.0000545120 uM-Replicate_1W615-Activity at 0.0001296300 uM-Replicate_1W615-Activity at 0.0003002588 uM-Replicate_1W615-Activity at 0.0006197232 uM-Replicate_1W615-Activity at 0.00170 uM-Replicate_1W615-Activity at 0.00522 uM-Replicate_1W615-Activity at 0.013 uM-Replicate_1W615-Activity at 0.030 uM-Replicate_1W615-Activity at 0.068 uM-Replicate_1W615-Activity at 0.153 uM-Replicate_1W615-Activity at 0.349 uM-Replicate_1W615-Activity at 1.067 uM-Replicate_1W615-Activity at 3.267 uM-Replicate_1W615-Activity at 8.386 uM-Replicate_1W615-Activity at 18.95 uM-Replicate_1W615-Activity at 42.46 uM-Replicate_1W615-Activity at 92.41 uM-Replicate_1W615-Activity at 240.3 uM-Replicate_1W615-Activity at 872.4 uM-Replicate_1W615-Activity at 1849.0 uM-Replicate_1W615-Activity at 4135.0 uM-Replicate_1W615-Activity at 9246.0 uM-Replicate_1W615-Activity at 20670.0 uM-Replicate_1W615-Activity at 46230.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive100046.71165.91411.01090.48573.26231.84362.00641.99435.44978.12683.9593.84525.64976.711610004-2.748
Inactive100041.15973.45360.9481-0.52418.4135-5.3381-0.2037-1.12098.426911.44892.56851.52615.51131.159710004-0.2798
Inactive1000413.619319.24979.80112.092519.851720.559717.738615.489515.20168.327325.730421.994613.226513.619310004-8.0616
Inactive10004-0.01774.084512.92615.3982.40380.8257.68639.482714.70655.1151-0.75927.9425-1.263-0.017710004-2.1171
Inactive100043.1252.35685.09388.475210.98810.10777.68738.07633.86263.49345.21091.85468.95053.12510004-15.6867
Inactive100047.46870.77720.070411.33447.3155.46854.97583.73919.3253-1.65574.71633.480410.62097.468710-8.61680.30.3731-11.65381840 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1384
Inactive10-5.36373.51170.3912-2-8.811940 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9865-8.0324-8.6353-2.0989-6.6589-13.3952-12.0664-9.0355-11.3374-6.2204-1.73390.0195-5.6888-2.986510004-24.5166
Activator37.79197.19310004-6.7723-1.27140.9157-4.0255-10.6032-5.96680.5902-3.4901-1.7017-13.963-2.6223-0.0117-2.2437-6.77230Partial curve; high efficacy-4.42261.22210.920696.8641-0.32892.10 0 0 0 0 0 0 0 0 0 0 0 0 0 081.1085
Inactive100041.5703-3.83490.9073-2.0903-1.2647-1.4311-3.4337-4.0019-0.4467-1.59621.99851.4791-3.3903-4.9221.570310004-4.9352
Inconclusive10004-0.6217-8.1939-9.7496-1.3131-1.96560.67370.907-13.3517-7.4235-3.3313-2.5924-1.9513-5.0812-0.62170Partial curve; partial efficacy; poor fit-4.51371.62590.7426-35.2959-4-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.4966
Inactive10004-0.97-4.3623-1.46539.6687-8.1041-8.3111-5.9686-3.301-4.21888.9934-5.42630-0.6903-0.9710004-9.314
Inactive10004-1.4457-6.89480.2171-2.9459-4.0435-7.3456-1.1919-9.5752-2.6175-0.3368-10.17-0.6414-0.3902-1.445710004-2.246
Activator9.678780.70610004-5.3519-9.0236-6.6327-5.8557-0.1803-16.2183-5.9643-10.6841-5.3049-7.3617-3.4598-16.9691-11.695-5.35190Partial curve; high efficacy-5.01420.80.925776.7855-3.92052.10 0 0 0 0 0 1 0 0 0 0 0 0 0 075.366
Inactive10004-2.6023-5.1436-20.2543-4.2156-18.6587-1.1774-0.484-24.4038-1.4626-19.5587-5.8609-4.7343-6.9928-2.602310-4.16370.90.3781-32.45411.727340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.2572
Inactive10-4.61370.90.4124-15.1446-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.347-0.3142-1.0420.9937-0.4332-5.17271.7846-9.5432-1.6937-2.2733-1.8768-12.2038-8.3511-0.347100041.5347
Inhibitor24.336570.80710004-0.78071.9061-0.7815-4.8851-12.66.6198-2.75363.05454.79781.16051.40111.6918-6.1939-0.78070Partial curve; partial efficacy-4.61371.69240.6988-64.3076.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 1-29.6108
Inactive10004-0.90493.2372.47662.64980.4207-1.39261.0889-11.66593.0536-1.96911.06293.9096-0.09-0.904910-6.26374.95490.42258.5-0.163240 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.6214
Inactive10-4.66371.46410.3698-14.6386-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.0234-8.0187-2.80042.58961.4724-2.46990.0707-3.28221.0981-1.2965-10.7454-0.5498-16.3655-11.023410004-27.7999
Inactive10-6.56424.95490.44474.5-3.852440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.6033-4.33852.27942.7066-14.0436-0.8758-9.51473.77765.08233.93465.49423.25690.88475.603310-6.76424.95490.3433-3.052140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-8.4886
Inhibitor18.49830.91151000413.22156.882221.7764.66487.65575.4813.49695.24837.72715.712213.43636.7754-1.020413.22150Partial curve; partial efficacy; poor fit-4.73294.95490.5896-30.65330.2582-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.5807
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC363
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197192 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.073 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 237.6 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.75414.95490.42033-4.98140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-4.9106-3.9228-5.9903-6.0515-1.4717-5.2912-7.602-5.9977-2.42-5.7364-8.2934-0.25662.9408-4.9106QC'd by SigmaAldrichInactive0
Inactive0004-3.3812-1.5662-16.55440.4975-4.09261.5304-12.9724-8.9269-1.91620.6198-11.0605-9.0324-13.3792-3.3812QC'd by SIGMAInactive0
Inactive00041.5277-10.1634-0.00874.0005-6.6661-6.69563.5741-1.09852.27453.2409-13.4326-7.2215-7.42071.5277QC'd by SigmaAldrichInactive0
Inactive0004-1.017-0.1246-23.0301-16.6405-6.1553-10.2548-6.5018-9.7542-2.401-3.4974.2117-8.21190.1193-1.017QC'd by SigmaAldrichInactive0-5.65984.95490.539
Inactive00043.38271.7071.93473.1752-3.8498-3.73072.23732.339-0.9899-3.4194-1.9669-9.73383.77663.3827QC'd by SIGMAInactive0
Inactive0004-0.73285.5587.8092.5786-0.96210.07372.9401-0.38870.14421.36820.83672.63761.7298-0.7328QC'd by SigmaAldrichInactive0
Inactive00042.35882.51021.81950.59232.94893.56280.6572-0.3826-0.85440.17520.73831.72051.81952.3588QC'd by Io-li-tecInactive0
Inactive00041.38781.00940.6532-1.03560.36512.28341.3107-16.37711.71522.1357-0.1164-0.65752.02321.3878QC'd by Io-li-tecInactive0
Inactive00045.46932.7258-1.71972.3804-20.79223.17021.6326-1.2539-13.72260.20822.47040.50210.58075.4693QC'd by SIGMAInactive0-5.85983.06540.6429
Inactive0-4.16644.0450.6851-12.45790.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.54830.2178-0.2309-0.79570.51171.13541.4003-0.03322.55783.2818-3.286-1.4703-0.7627-9.5483QC'd by SIGMAInactive0-4.36641.98870.8468
Inconclusive23.990430.144810Partial curve; partial efficacy; poor fit-4.620.70.747630-0.14482.40 0 0 0 0 0 0 0 0 0 0 0 0 0 022.60371.2906-5.817-1.8818-7.2041.07217.41797.545.08272.19837.159913.888719.365422.6037QC'd by SIGMAInactive0-4.120.50.4
Inactive00042.59482.69211.2072-3.7186-4.66812.76633.94650.38173.5477-0.23396.89892.65815.70112.5948QC'd by AcrosInactive0
Inactive0-4.19134.0450.813213-1.521440 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5641-2.86591.25950.2725-1.1592-2.4294-2.1941.7532-2.4893-1.6357-0.1925-1.74781.073610.5641QC'd by SIGMAInactive0
Inactive00047.9141-1.9689-2.253-4.53782.2968-12.15473.36423.88694.99273.8103-8.57025.75174.7237.9141QC'd by SIGMAInactive0
Cytotoxic30.357783.203640Partial curve; high efficacy-4.51771.55790.9633-85.4248-2.2213-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.09710.1445-3.4687-6.33-5.4346-2.1394-5.5181-4.45781.539-0.7887-20.6233-25.9409-48.5781-79.0971QC'd by SIGMACytotoxic60.571591.352241Partial curve; high efficacy-4.21771.3310.9211
Inactive0-4.11374.95490.508311-1.19640 0 0 0 0 0 0 0 0 0 0 0 0 0 07.6371-0.9966-6.4133-1.62961.9829-2.5154-0.6080.0257-0.63170.3616-2.9777-3.0149-0.89117.6371QC'd by SIGMAInactive0
Cytotoxic69.777181.308620Single point of activity-4.15634.95490.9502-84.9425-3.6339-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.79571.365-8.0975-1.71050.6639-11.5921-1.7071-5.2425-4.18560.7387-7.358-7.5217-8.401-69.7957QC'd by SigmaAldrichCytotoxic69.777178.320620Single point of activity-4.15634.95490.9859
Inactive0004-13.1552-4.8346-4.34493.2135-7.58344.6528-8.09981.1002-3.0242.43910.6845-2.3657-3.4277-13.1552QC'd by SigmaAldrichInactive0-6.31074.95490.4218
Inactive0004-22.127-12.1698-7.5453-6.5016-5.9755-2.61933.5381-1.3673-14.7241-1.0064-4.7639-6.1963-2.5303-22.127QC'd by InterchemCytotoxic69.567322.86820Single point of activity-4.15764.95490.8014
Inactive0004-5.0254-5.9486-2.7845-5.6405-2.1794-5.01680.8851-0.4331-4.3384-8.3171-7.9408-6.7025-12.8316-5.0254QC'd by SigmaAldrichInactive0-7.15934.95490.3077
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Bile salt export pump
External ID: CHEMBL4011663
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Toxicol Sci
Year: 2010
Volume: 118
Issue: 2
First Page: 485
Last Page: 500
DOI: 10.1093/toxsci/kfq269

Target ChEMBL ID: CHEMBL6020
ChEMBL Target Name: Bile salt export pump
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
5.9IC50=5900nM
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
37.8IC50=37800nM
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
135IC50>135000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC907
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30-minute incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000060039 uM-Replicate_1Activity at 0.0000137707 uM-Replicate_1Activity at 0.0000545120 uM-Replicate_1Activity at 0.0001296300 uM-Replicate_1Activity at 0.0003002588 uM-Replicate_1Activity at 0.0006197232 uM-Replicate_1Activity at 0.00170 uM-Replicate_1Activity at 0.00522 uM-Replicate_1Activity at 0.013 uM-Replicate_1Activity at 0.030 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.349 uM-Replicate_1Activity at 1.067 uM-Replicate_1Activity at 3.267 uM-Replicate_1Activity at 8.386 uM-Replicate_1Activity at 18.95 uM-Replicate_1Activity at 42.46 uM-Replicate_1Activity at 92.41 uM-Replicate_1Activity at 240.3 uM-Replicate_1Activity at 872.4 uM-Replicate_1Activity at 1849.0 uM-Replicate_1Activity at 4135.0 uM-Replicate_1Activity at 9246.0 uM-Replicate_1Activity at 20670.0 uM-Replicate_1Activity at 46230.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-7.31554.95490.55256-10.506740 0 0 0 0 0 0 0 0 0 0 0 0 0 01.801-5.491-7.986-20.8389-13.33246.28051.45194.0156-1.49715.503217.479718.13128.25281.801QC'd by SIGMAInactive0
Inactive0-5.55854.95490.414910-3.634840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.8804-1.78583.6024-6.131-18.86241.55921.63912.0415-8.03311.875915.20442.08323.413816.8804QC'd by SigmaAldrichInactive0
Inactive00048.71311.8866-1.71662.80311.5009-12.00410.7575.6763-5.58230.5326-1.94871.56463.21748.7131QC'd by SIGMAInactive0
Inactive00041.38123.09412.98235.29743.65263.73992.58423.992310.1669.33368.2397-3.59293.03941.3812QC'd by SigmaAldrichInactive0
Inactive0-5.21022.18760.708121.3899-4.687740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.7888-7.3321-7.2161-5.9695-3.47354.0032.56842.7648-12.70273.788413.36314.120524.94961.7888QC'd by ChemServiceInactive0
Inhibitor19.2133337.934344Partial curve; high efficacy-4.71640.50.8478-333.03594.8984-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-252.2999-0.7118-0.9263-5.706-0.121-7.8262-19.3177-30.6174-72.0512-141.5323-123.9442-69.283-223.2304-252.2999QC'd by CytecInhibitor0.541591.790188Complete curve; high efficacy-6.26642.24810.8093
Inactive000416.32936.1544-16.59613.5287-3.494911.62383.5327-5.0571-6.0458-18.6327-4.28816.37352.673916.3293QC'd by SigmaAldrichInactive0
Inactive0-4.55674.95490.4793-23.369-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.59612.49199.058-0.042.1764-12.5203-9.6302-4.47431.7432-2.4338-7.1101-1.5691-22.8075-11.5961QC'd by SIGMAInactive0
Inactive0-4.12184.95490.449526-2.605540 0 0 0 0 0 0 0 0 0 0 0 0 0 020.619-2.119910.8862-0.6531.1832-6.5161-12.30681.6601-2.4009-5.2525-1.0688-1.081-15.921220.619QC'd by SigmaAldrichInactive0
Inhibitor39.277963.752610Partial curve; partial efficacy; poor fit-4.405910.5919-69.8334-6.0808-2.40 0 0 0 0 0 0 1 0 0 0 0 0 0 0-50.3057-6.0808-3.833-13.0728-18.3166-16.1035-3.3344-39.328-14.4105-11.2535-19.6606-3.471-55.4233-50.3057QC'd by SigmaAldrichInactive0
Inactive0-4.30931.3310.825428440 0 0 0 0 0 0 0 0 0 0 0 0 0 021.58514.24835.69328.56476.9910.88430.9534.82571.8614.69056.67246.912515.164121.5851QC'd by SIGMAInactive0-8.80934.95490.3266
Inactive0-7.01910.20.430317.5-12.668140 0 0 0 0 0 0 0 0 0 0 0 0 0 010.0881-3.90832.3807-10.14017.97570.438612.25-0.05663.12176.070511.49712.456319.720110.0881QC'd by SigmaAldrichInactive0
Inactive0-4.86681.98870.55326.9348-3.820740 0 0 0 0 0 0 0 0 0 0 0 0 0 11.3376-7.6928-0.53331.7983-4.65540.58472.4554-8.8369-11.17517.03152.967515.389924.36441.3376QC'd by ChemServiceInactive0
Inactive0-4.13584.95490.546-35.94241.49140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-28.27790.98835.171-5.248411.3338-0.09311.90132.24583.6879-3.4241-9.6853-6.06656.4942-28.2779QC'd by ChemServiceInactive0-5.88580.30.6749
Activator59.332235.05150Single point of activity-4.22673.990.833838.53.448530 0 0 0 0 0 0 0 0 0 0 0 0 0 033.30954.22966.671610.30334.46525.68211.882812.80621.179613.60763.64714.72757.038733.3095QC'd by SIGMAInactive0
Inactive0004-18.3735-7.17083.2132-14.43274.2935-17.38060.81161.09940.61580.3307-12.4961.5395-1.1314-18.3735QC'd by SIGMAInactive0
Inactive0-4.86151.88510.4207-25.5319-140 0 0 0 0 0 0 0 0 0 0 0 0 0 112.5765-5.8516-15.33963.9162-1.52163.46663.89890.63135.3836-14.6469-0.8588-20.291-21.276612.5765QC'd by SIGMAInactive0-4.86150.30.6157
Activator69.3576284.63330Partial curve; high efficacy-4.15894.95490.9582290.23735.60392.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0239.46977.4741-0.21950.527-1.08286.48486.11090.902420.65386.373815.29646.5792-2.3841239.4697QC'd by SIGMAActivator69.3576259.95740Single point of activity-4.15894.95490.9713
Inactive0-8.81644.95490.4623-26.538540 0 0 0 0 0 0 0 0 0 0 0 0 0 08.1952-9.4853-0.73863.1728-13.46198.36624.0971-0.382711.06927.1292-0.8452-3.79372.19738.1952QC'd by SIGMAInactive0-4.11644.95490.4257
Inactive0-5.16024.95490.810517-5.339140 0 0 0 0 0 0 0 0 0 0 0 0 0 020.0371-5.3775-5.3595-10.6992-6.74984.98782.3993-9.0254-6.8107-9.764111.372511.406218.847720.0371QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: HIF170
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W530-Activity_Score-Replicate_1W530-Curve_Description-Replicate_1W530-Fit_LogAC50-Replicate_1W530-Fit_HillSlope-Replicate_1W530-Fit_R2-Replicate_1W530-Fit_InfiniteActivity-Replicate_1W530-Fit_ZeroActivity-Replicate_1W530-Fit_CurveClass-Replicate_1W530-Excluded_Points-Replicate_1W530-Max_Response-Replicate_1W530-Activity at 0.0000049734 uM-Replicate_1W530-Activity at 0.0000113459 uM-Replicate_1W530-Activity at 0.0000446985 uM-Replicate_1W530-Activity at 0.0001080938 uM-Replicate_1W530-Activity at 0.0002492385 uM-Replicate_1W530-Activity at 0.0005106135 uM-Replicate_1W530-Activity at 0.00140 uM-Replicate_1W530-Activity at 0.00426 uM-Replicate_1W530-Activity at 0.011 uM-Replicate_1W530-Activity at 0.025 uM-Replicate_1W530-Activity at 0.057 uM-Replicate_1W530-Activity at 0.128 uM-Replicate_1W530-Activity at 0.291 uM-Replicate_1W530-Activity at 0.878 uM-Replicate_1W530-Activity at 2.670 uM-Replicate_1W530-Activity at 7.009 uM-Replicate_1W530-Activity at 15.84 uM-Replicate_1W530-Activity at 35.48 uM-Replicate_1W530-Activity at 76.84 uM-Replicate_1W530-Activity at 198.7 uM-Replicate_1W530-Activity at 725.3 uM-Replicate_1W530-Activity at 1537.0 uM-Replicate_1W530-Activity at 3438.0 uM-Replicate_1W530-Activity at 7687.0 uM-Replicate_1W530-Activity at 17190.0 uM-Replicate_1W530-Activity at 38440.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10004-3.6553-0.9893-3.5818-1.17650.2463-0.2234-0.9145-0.01270.2733-0.26810.30620.5194-3.3182-3.655310004-0.2957
Inactive100041.82260.0462.81770.4783.4369-1.20180.3150.57551.36561.70740.581-1.5460.3161.822610004-0.7107
Inconclusive21.313826.487710Partial curve; partial efficacy-4.67131.88510.9421270.51232.20 0 0 0 0 0 0 0 0 0 0 0 0 0 020.1544-1.23981.60671.0591-0.37590.27121.8173-0.79810.55232.50490.08824.576511.091520.154410004-3.7146
Inactive10-5.27134.95490.37923.5-0.39640 0 0 0 0 0 0 0 0 0 0 0 0 0 11.11-0.22040.39841.729-2.1419-1.0363-2.83-0.8962-0.41591.0879-0.28773.13323.13221.11100040.2226
Inconclusive20.596119.464310Partial curve; partial efficacy; poor fit-4.68620.20.358-21.5626-2.0984-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.687-4.9503-10.9522-8.9046-1.6211-0.082-5.788-7.8292-6.4939-9.6741-10.0897-14.9287-16.3022-10.68710004-0.8617
Inconclusive3.023217.722210Partial curve; partial efficacy; poor fit-5.51950.40.6216-23.6128-5.8906-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-12.9702-7.4334-8.7638-12.1242-3.2422-6.6164-6.414-17.1247-10.8286-15.8444-16.4368-20.094-16.7283-12.970210-8.96954.95490.78710.9737.540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1086
Inactive100041.5223-1.7357-0.7438-3.6994-0.395-0.29530.4241-3.0256-2.7235-1.8125-1.1286-0.6724-2.7321.522310004-0.2476
Inactive10004-12.8642-6.1115-9.8495-9.2614-3.1038-3.26460.1035-13.4348-10.1594-9.5645-9.6545-16.3803-14.6367-12.8642100040.3025
Inactive10004-0.0604-2.1693-3.4849-0.6126-2.4801-0.7035-2.75370.0219-1.0218-2.56510.0598-5.2827-0.7625-0.0604100040.3359
Inactive10004-3.46910.5975-4.6703-1.7651-0.7229-3.1804-0.9474-1.3234-0.6065-3.7492-3.479-2.4871-0.3194-3.4691100042.2474
Inactive10-6.7751.10.3519-3.6702-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.9024-0.0717-0.9296-1.0266-2.29810.7439-3.8561-0.582-2.5247-7.2252-4.5423-1.3126-2.0748-0.9024100043.0923
Inactive10004-9.8666-1.1348-6.2751-5.2223-1.99990.0905-0.7847-3.2022-1.5132-2.9373-4.0064-4.484-6.056-9.8666100041.8718
Inactive10004-8.9364-1.2425-5.5217-3.44221.1273-2.75941.619-1.0059-2.884-3.0865-4.52-3.9722-9.247-8.936410-4.40651.66040.93388.5140 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1016
Inconclusive10.276517.852710Partial curve; partial efficacy; poor fit-4.98820.60.445-20.2075-2.3548-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.1898-3.0172-8.3806-7.0506-3.6035-1.3277-0.2956-8.0513-1.2813-9.1424-7.6654-15.1729-14.3238-7.189810004-1.0635
Inactive10-5.74990.60.6027-15.0694-4.122240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-11.8447-4.9088-8.1722-1.7685-3.24-3.1309-4.6399-11.5479-7.3956-9.2891-12.3039-14.1602-14.2245-11.8447100043.318
Inconclusive4.395417.188910Complete curve; partial efficacy; poor fit-5.3570.80.5163-25.9259-8.737-1.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.6982-6.7445-16.6319-7.1908-5.879-5.5985-3.9475-15.8575-10.3684-14.7455-20.4174-24.9382-21.2805-18.6982100044.3064
Inactive10004-13.1388-3.3075-12.7272-9.0493-9.8786-7.1457-2.8049-12.1577-10.9471-13.3333-12.2337-20.0526-10.5047-13.1388100041.101
Inactive10-4.89190.90.709-13.2479-140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.6909-2.1257-2.7415-1.45671.4230.53370.4156-2.3538-1.045-5.073-2.362-8.7847-11.0399-3.6909100041.1903
Inactive10-4.64144.95490.57843.5-1.853540 0 0 0 0 0 0 0 0 0 0 0 0 0 01.62650.4697-2.8233-2.4-4.4612-1.6658-0.927-1.6545-0.2803-2.145-0.0407-1.23645.26151.6265100041.1602
Inactive10-4.56044.95490.54737-1.629440 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1793-2.1537-0.4036-2.87041-5.5245-0.3415-3.2205-1.4272-0.2922-5.2662-2.17246.53540.1793100040.9083
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: H2AX721
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 3 uL/well CellTiter-Glo luminescent cell viability reagent (Promega Corporation, Madison, WI) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After incubation at room temperature for 30 min, the luminescence intensity was read using a ViewLux plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000100212 uM-Replicate_1Activity at 0.0000229890 uM-Replicate_1Activity at 0.0000909942 uM-Replicate_1Activity at 0.0002163761 uM-Replicate_1Activity at 0.0005012188 uM-Replicate_1Activity at 0.00103 uM-Replicate_1Activity at 0.00284 uM-Replicate_1Activity at 0.00871 uM-Replicate_1Activity at 0.022 uM-Replicate_1Activity at 0.051 uM-Replicate_1Activity at 0.114 uM-Replicate_1Activity at 0.255 uM-Replicate_1Activity at 0.582 uM-Replicate_1Activity at 1.781 uM-Replicate_1Activity at 5.430 uM-Replicate_1Activity at 14.00 uM-Replicate_1Activity at 31.63 uM-Replicate_1Activity at 70.87 uM-Replicate_1Activity at 154.2 uM-Replicate_1Activity at 401.1 uM-Replicate_1Activity at 1455.9 uM-Replicate_1Activity at 3087.0 uM-Replicate_1Activity at 6902.0 uM-Replicate_1Activity at 15430.0 uM-Replicate_1Activity at 34510.0 uM-Replicate_1Activity at 77170.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic0.195816.579320Single point of activity-6.70814.95490.6356-17.0793-0.5-30 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.0378-0.07892.0497-4.0824-1.52491.28180.3598-15.06615.2629-1.5796-2.6816-2.6592-1.481-0.0378QC'd by ACCInactive0-7.95813.990.358
Inactive043.2303-5.2610.91491.7511-0.9651.5180.41441.2813-4.8181-8.566-3.01530.40231.03723.2303QC'd by ACCInactive0
Inactive042.6334-0.4566-0.24132.79170.73373.49855.35830.74840.4867-0.23133.50311.23690.75822.6334QC'd by ACCInactive0
Inactive045.14512.97753.87223.1624-2.6383-1.7577-2.117110.59053.2733-0.5395-0.05624.28030.11225.1451QC'd by ACCInactive0
Inactive04-3.6748-2.4298-0.6747-3.1974-7.4289-2.8005-2.60937.3711-4.7494-6.4707-2.9423-3.1292-6.3414-3.6748QC'd by RTIInactive0
Inactive0-4.106310.6242-13.9734-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.97781.6144-1.4479-3.95650.076-5.6314-1.40311.244-2.3399-2.0506-1.5683-5.5983-6.2459-9.9778QC'd by RTIInactive0
Inactive0-4.21014.0950.3917-6.2749-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.0624-0.57771.191-3.8357-1.4631-1.6187-3.87122.41012.2699-1.78380.574-1.198-4.7749-6.0624QC'd by RTIInactive0
Inactive04-6.2845-6.4479-2.6819-0.9491-5.5321-3.63081.9302-1.1485-4.5456-3.1284-3.4839-2.2626-3.9496-6.2845QC'd by RTIInactive0
Inactive0-3.450.90.4298-13.7287-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.7739-0.5915-0.5427-2.26743.129-4.3159-3.0773-0.4174-0.3897-1.8236-7.365-0.639-3.1035-9.7739QC'd by RTIInactive0
Cytotoxic45.904415.988820Complete curve; partial efficacy-4.33814.95490.8599-16.9888-1-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.3573-1.6405-0.1185-4.391-3.34390.26140.1829-2.90071.2236-2.46020.516-3.2239-17.4906-15.3573QC'd by RTICytotoxic57.790219.151620Complete curve; partial efficacy-4.23814.95490.6765
Inactive0-4.41173.990.8619-10.9831-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.9372-2.0267-0.9393-1.66530.09420.2489-2.1983-0.5132-2.20040.1676-1.8927-6.1292-13.3192-8.9372QC'd by RTIInactive0
Cytotoxic94.101494.77642Partial curve; high efficacy-4.02643.1320.9876-95.3228-0.5468-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.79-2.37250.2589-3.28970.7307-1.0945-0.847-1.70852.7324-3.2271-0.0239-0.2899-30.464-79.79QC'd by RTICytotoxic105.583587.355742Partial curve; high efficacy-3.97644.44950.9851
Cytotoxic127.898275.716942Partial curve; high efficacy-3.89311.210.7142-78.6996-2.9828-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-59.6209-1.1995-2.582-0.801-0.7702-5.2133-6.0E-4-3.9281-0.099-7.38-6.3771-34.7211-7.476-59.6209QC'd by RTICytotoxic28.6328123.74920Single point of activity-4.54312.40640.8306
Inactive0-3.97460.60.6973-12.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.78030.9175-2.09581.2549-1.23831.43091.0801-2.1662-2.6553-2.8983-4.02-2.9099-5.1369-8.7803QC'd by RTICytotoxic118.957316.037320Partial curve; partial efficacy; poor fit-3.92460.90.7158
Cytotoxic91.940426.641821Partial curve; partial efficacy-4.03653.06540.9323-27.1418-0.5-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.86820.53250.7878-0.5764-0.2246-2.89571.3672-1.4009-2.8906-2.8280.19151.1536-10.4047-23.8682QC'd by RTICytotoxic73.030925.702821Partial curve; partial efficacy-4.13653.51170.9553
Cytotoxic90.445521.118220Partial curve; partial efficacy; poor fit-4.04361.88510.6485-24.6182-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.1818-3.5991-0.9613-8.8603-5.261-1.9156-2.4825-12.1501-2.5401-0.8207-5.1003-2.8595-12.2432-22.1818QC'd by RTICytotoxic80.609621.332220Partial curve; partial efficacy-4.09361.88510.8349
Inactive04-7.93740.9285-2.2382-1.0931-2.5705-6.96450.1194-2.3351-0.81211.284-0.7640.8797-5.3686-7.9374QC'd by RTIInactive0
Inactive04-4.5331-1.6685-2.39040.58240.2176-2.6217-3.9140.73360.0474-3.1743-0.0069-2.8617-8.6171-4.5331QC'd by RTIInactive0-5.47880.30.7769
Inactive04-2.3056-1.4405-2.2094-1.8577-1.6091-0.00590.1594-1.4245-0.9456-2.1159-0.5644-1.3464-4.2856-2.3056QC'd by RTIInactive0
Inactive0-4.29720.70.5972-7.6054-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.4403-1.6095-0.4996-0.9438-1.2942-0.94991.0478-1.6707-1.3686-1.0617-4.9494-1.064-5.5045-5.4403QC'd by RTIInactive0-3.89720.40.4901
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: HIF512
Protocol: Tox21 Assay Protocol Summary:

HRE-bla ME-180 cells were dispensed at 2,000 cells per well in 6 uL of assay medium containing 0.5% dialyzed FBS into black wall/clear-bottom 1536-well plates using a Multidrop Combi (Thermo Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 hrs, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to each well of the assay plate using a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C and 5% CO2 for 17 hrs. One uL of LiveBLAzerTM B/G FRET substrate (CCF4-AM) (Life Technologies) was added to each well using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). After 2 hr incubation at room temperature, fluorescence intensity (405 nm excitation, 460 nm and 530 nm emissions) was measured using an Envision plate reader (PerkinElmer, Shelton, CT). For cytotoxicity, 4 ul/well of CellTiter-Glo reagent was added into the assay plates using an FRD. After 30 min incubation at room temperature, the luminescence intensity was measured using a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152025 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.60324.0950.64957-2.700740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.1758-4.2575-0.8849-0.5073-1.8009-7.6673-2.86610.1917-0.6812-1.2122-5.0182-1.00364.92727.1758QC'd by TCIInactive0-7.15323.990.4691
Inactive0-6.75750.20.6588-24.3563-0.170840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.4636-4.8496-8.5344-10.1028-14.3441-10.343-14.2235-11.4306-14.1952-18.1832-11.9322-14.9262-14.9623-24.4636QC'd by SIGMAInactive0-7.55751.62660.7962
Inactive00040.5977-0.7538-0.8916-2.8779-3.0565-5.0177-5.8497-6.2902-0.3941-5.3169-0.7029-2.38370.72570.5977QC'd by ChemServiceCytotoxic17.561183.395741Partial curve; high efficacy-4.75541.62590.9741
Inactive0-4.45440.60.6816-30.3523-2.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.3769-4.6229-0.5495-1.2895-1.1193-12.13114.0955-0.9288-5.7619-9.7965-12.511-12.2886-12.1517-22.3769QC'd by CrescentInactive0
Inactive0-4.95441.88510.9636-30.318-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.03140.50570.3708-1.2987-0.0781-5.2462-1.11230.80840.2592-2.641-8.1573-19.3031-30.265-26.0314QC'd by SIGMACytotoxic22.159172.288720Single point of activity-4.65444.95490.9483
Inactive0-4.20384.50450.676616-2.965540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.8414-4.0057-0.109-1.78660.0869-3.6625-9.5546-4.9082-0.61-2.786-4.3728-2.7969-1.836410.8414QC'd by SigmaAldrichInactive0
Inactive0-4.94951.82650.9274-33.9853-61.540140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.7609-60.7983-57.7742-60.0884-64.8103-59.1302-65.3149-63.658-60.1957-60.6665-54.3555-43.9534-33.3211-38.7609QC'd by SigmaAldrichInactive0
Inactive0004-4.1397-2.9877-1.83381.1979-10.7008-1.7544-1.1569-2.2875-3.3128-2.3864-5.2743-0.26821.7528-4.1397QC'd by SigmaAldrichInactive0-4.70584.95490.7058
Inactive0004-5.8179-5.051-0.68060.5857-0.6234-4.5622-3.8615-1.3297-3.5351-8.9704-10.877-7.88430.1856-5.8179QC'd by SigmaAldrichInactive0-4.3742.33320.6555
Inactive0004-9.9825-1.6216-0.6635-5.2568-0.7064-0.73850.4011-0.9831-5.9428-1.712-6.379-8.825-0.6433-9.9825QC'd by SigmaAldrichInactive0
Inactive0004-8.24010.7083-12.582-1.555-1.5841-0.99266.0648-10.9222-9.8317-1.6314-19.7387-9.04398.5004-8.2401QC'd by SIGMAInactive0
Inactive0-4.91454.95490.540912.51.574440 0 0 0 0 0 0 0 0 0 0 0 0 0 09.3217-0.14334.82590.34674.15480.21845.10389.20720.90632.8403-5.354612.657214.18879.3217QC'd by SensientCytotoxic10.850938.753621Partial curve; partial efficacy-4.96451.88510.985
Cytotoxic38.168351.019720Partial curve; partial efficacy-4.41832.40640.7543-52.141-1.1213-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.531-0.30450.3523-3.7746-0.08513.3224-0.4139-0.226-9.87290.41153.59950.7027-26.9055-42.531QC'd by SIGMAInactive0-4.26834.95490.9124
Inactive00046.73872.7960.1416.00960.266.04240.29035.3783-10.3279-1.3301-1.98070.55341.0526.7387QC'd by SIGMAInactive0-6.55683.06540.7495
Inactive0-4.41582.72020.499213.5-0.204840 0 0 0 0 0 0 0 0 0 0 0 0 0 011.4311-0.1318-0.1192-2.1669-2.4026-0.47710.5652-2.26862.29990.1723-0.219-0.32865.908511.4311QC'd by SIGMAInactive0-5.06583.92950.3811
Inactive0004-1.37410.25470.5081.221-1.343-2.0309-0.68440.0949-1.60341.0326-4.1250.2241-1.2696-1.3741QC'd by SIGMAInactive0
Inactive0-4.39741.10.4549-0.393740 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3303-2.31921.414-4.9114-0.3542.6407-0.15680.74260.3671-0.05451.08881.48262.55997.3303QC'd by SIGMAInactive0
Inactive00044.0189-2.49471.2236-0.56551.1538-2.0889-2.06983.13650.5040.18410.37760.58323.45024.0189QC'd by SIGMAInactive0
Inactive00044.07422.03523.4602-0.6876-0.18963.1220.24180.43210.3714-0.80881.43034.6376-1.94074.0742QC'd by FLUKAInactive0-6.37634.95490.551
Inactive0-5.44954.95490.41323.5-1.067440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8554-0.2996-0.2381-3.8228-0.2096-3.80041.63590.3602-2.58850.23935.5561.53523.7894-2.8554QC'd by SIGMAInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: H2AX604
Protocol: Tox21 Assay Protocol Summary:

The CHO-K1 cells suspended in culture medium containing 10% FBS were dispensed at 1000 cells/ 3 ul/well in 1536-well white wall/solid bottom plates (Greiner Bio-One North America, NC) using a Multidrop Combi (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37C overnight, 23 nl of compounds at 15 concentrations (from 5-48 columns) or positive control (from 1 to 4 columns) were transferred to the assay plates using a Pintool station (Wako, San Diego, CA) into each well resulting in a final DMSO concentration of 0.76%. After 3hr incubation at 37C, 1 uL/well Supplemented Lysis buffer (diluted 100 fold blocking reagent in lysis buffer) (HTRF Phospho-H2A.X (S139) Assay kit from Cisbio US Inc., Bedford, MA) was added using a Flying Reagent Dispenser (FRD) (Aurora Discovery, CA). After 10sec spin at 1000 rpm in a plate centrifuge, the assay plates were incubated at room temperature for 30 min. Then followed by the addition of 1 uL/well detection buffer (containing a mixture of two antibodies, one labeled with cryptate, Anti pH2AX (S139)-K and another labeled with d2, Anti H2AX-d2) using FRD. After incubation at room temperature for 24 hr, the time resolved fluorescence at excitation 320 nm and emissions at 665 nm and 620 nm was measured using an Envision plate reader (PerkinElmer, Waltham, MA).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W620-Activity_Score-Replicate_1W620-Curve_Description-Replicate_1W620-Fit_LogAC50-Replicate_1W620-Fit_HillSlope-Replicate_1W620-Fit_R2-Replicate_1W620-Fit_InfiniteActivity-Replicate_1W620-Fit_ZeroActivity-Replicate_1W620-Fit_CurveClass-Replicate_1W620-Excluded_Points-Replicate_1W620-Max_Response-Replicate_1W620-Activity at 0.0000100212 uM-Replicate_1W620-Activity at 0.0000229890 uM-Replicate_1W620-Activity at 0.0000909942 uM-Replicate_1W620-Activity at 0.0002163770 uM-Replicate_1W620-Activity at 0.0005012188 uM-Replicate_1W620-Activity at 0.00103 uM-Replicate_1W620-Activity at 0.00284 uM-Replicate_1W620-Activity at 0.00871 uM-Replicate_1W620-Activity at 0.022 uM-Replicate_1W620-Activity at 0.051 uM-Replicate_1W620-Activity at 0.114 uM-Replicate_1W620-Activity at 0.255 uM-Replicate_1W620-Activity at 0.582 uM-Replicate_1W620-Activity at 1.781 uM-Replicate_1W620-Activity at 5.453 uM-Replicate_1W620-Activity at 14.00 uM-Replicate_1W620-Activity at 31.63 uM-Replicate_1W620-Activity at 70.87 uM-Replicate_1W620-Activity at 154.2 uM-Replicate_1W620-Activity at 401.1 uM-Replicate_1W620-Activity at 1455.9 uM-Replicate_1W620-Activity at 3087.0 uM-Replicate_1W620-Activity at 6902.0 uM-Replicate_1W620-Activity at 15430.0 uM-Replicate_1W620-Activity at 34510.0 uM-Replicate_1W620-Activity at 77170.0 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1
Inactive10-6.95810.40.4668-1.3477-7.973440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4019-5.4309-8.3112-7.4244-5.4208-0.6969-6.5272-2.9697-6.5206-4.8941-0.5496-0.9734-3.7779-2.4019104-0.1994
Inactive104-0.8865-1.2427-0.10122.7689-1.2051-8.0331-5.6601-3.2832-1.2739-1.30180.9228-3.4270.4966-0.8865104-1.2268
Fluorescent55.196533.330110Single point of activity-4.25811.92820.698632-1.330130 0 0 0 0 0 0 0 0 0 0 0 0 0 023.3727-5.2171-8.1918-2.84561.0030.09960-2.16164.727-5.48962.26846.26634.656323.372710-8.20812.24810.3141-1.0212240 0 0 0 0 0 0 0 0 0 0 0 0 0 00.5571
Inactive104-3.0709-9.96180.7982-5.2192-0.5692-7.4363-1.8669-1.2646-6.986367.4176-2.9179-3.7281-0.9825-3.07091042.655
Inactive10-7.72294.95490.339-1.7182240 0 0 0 0 0 0 0 0 0 0 0 0 0 02.61022.22290.57310.318-2.5399-0.2987-1.5265-3.9318-3.3363-3.134-1.9675-1.7341.76152.6102104-0.1089
Inactive1042.7579-1.57941.15321.1346-2.0421.2942-1.69611.24990.9043-2.1472-3.28342.9771-3.35412.7579104-2.7282
Inactive1040.3103-6.58781.75191.80410.9792-3.4345-4.0663-4.2039-4.2626-3.1864-0.08561.4332-0.7270.31031043.6137
Inactive104-1.1081-6.8305-4.7329-5.9552-0.0549-6.737-0.7996-9.2941-6.0746-0.5427-2.1729-2.8132-2.3094-1.10811040.5597
Inactive10-8.350.90.4324-1-10.594340 0 0 0 0 0 0 0 0 0 0 0 0 0 03.4474-5.3962-0.0826-3.1558-1.3558-0.4378-3.4408-2.8376-1.0188-0.97340.8621-1.9522-1.96323.4474104-4.44
Inactive104-0.7343-8.0348-3.0411-0.1542-1.28041.7882-1.1388-9.1341-4.2303-2.967-1.0623-1.1713-0.1655-0.734310-3.78814.95490.5013-5.32120.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.7677
Inactive10-6.71171.62660.3188-0.5-2.820840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.2805-0.0514-4.2641-2.6332-4.8507-0.5406-1.432-1.41880.7593-1.54291.0907-1.0329-2.0198-1.28051040.481
Inactive104-11.2334-7.1625-2.2867-5.4475-3.7778-2.3395-7.3034-0.3656-3.4483-9.3653-5.5476-10.4351-11.3637-11.23341044.3704
Inactive104-2.86241.0493-2.5635-1.9363-0.226-2.2897-2.38710.5577-1.1759-2.1626-3.16020.4219-0.9845-2.86241042.242
Inactive104-1.6903-1.0786-2.1965-1.3298-0.06540.0541-3.2054-1.5765-5.5016-5.03210.1563-0.4334-3.7092-1.69031040.1926
Inactive1041.1876-1.5971-4.1158-1.27110.0502-3.6804-4.3519-3.952-1.267-0.0663-0.569-7.508-2.8771.18761041.4021
Inactive1040.24620.6799-1.6187-2.99681.55590.7002-0.4152-0.23540.933-1.4204-2.95051.2689-2.16810.2462104-1.6194
Inactive104-2.21620.1318-2.90266.8735-2.20941.0407-1.7947-2.3121-4.59980.82981.171-5.44561.1958-2.2162104-2.9548
Inactive1040.65650.6163-1.1595-0.8031-2.2181.3415-4.049-3.3028-3.4787-2.39650.1898-0.73210.38440.6565104-1.8324
Inactive1041.1241-8.5235-3.20041.8669-4.8174-0.1069-0.6147-2.4142-1.0633-2.48770.1282-1.2367-1.58931.12411040.1357
Inactive10-6.94720.80.4048-0.5-3.161940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1519-2.2985-3.492-1.744-3.1132-2.3395-0.2181-1.8917-0.8137-1.06751.9967-2.542-1.2665-3.15191040.9974
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV463
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive041.72950.52943.18025.8576-13.2261-2.70962.32773.08360.66810.8553-2.5716-8.80020.93361.7295QC'd by ACC0
Inactive0-5.67134.95490.4567-9.5364-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.4931-0.3132-9.0031-1.37862.9342-0.62741.4692.0742-1.31910.8343-7.1697-14.1560.3555-9.4931QC'd by ACC0
Activator16.9301626.649349Partial curve; high efficacy-4.77131.3310.9768639.241312.5922.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0495.5359-1.9437-0.28722.264960.37582.736523.80731.9884.584813.458684.9728135.6152319.9522495.5359QC'd by ACC0
Inactive0-9.17134.95490.3243-4.16692440 0 0 0 0 0 0 0 0 0 0 0 0 0 14.49519.1079-2.92392.9475-1.1252-3.1158-19.7224-18.7137-5.55731.73914.3407-0.5794-17.21864.495QC'd by ACC0
Inactive04-1.4338-5.1613-13.4065-11.08192.2196-9.8309-7.493519.6175-11.68-6.5454-3.0084-1.3924-0.0854-1.4338QC'd by RTI0
Inactive04-0.06572.7267-14.8963-0.59042.5835-4.97911.54130.4423-5.1268-14.4299-8.05080.6303-10.6572-0.0657QC'd by RTI0
Inactive04-2.2898-1.05085.84332.72411.9566-1.76592.149-5.0045-8.03727.387518.2729-3.414514.9169-2.2898QC'd by RTI0
Inactive04-2.66921.559137.22210.9092.2412.8103-4.2918-5.3244-6.3058-0.6797-2.999917.4880.0577-2.6692QC'd by RTI0
Inactive04-7.8369-7.29973.8528-6.08521.198756.327-0.252-6.6076-2.0431-2.85932.836660.13680.7004-7.8369QC'd by RTI0
Inactive0-7.90134.44950.42791-11.008940 0 0 0 0 0 0 0 0 0 0 0 0 0 01.1506-12.4702-10.9207-3.67122.24471.34810.8136-4.3714.0377-2.89721.43973.8914-3.2241.1506QC'd by RTI0
Inactive041.11810.1768-5.3052-0.94990.09024.06750.0846-0.6164-0.42438.7148-3.13170.6008-2.02271.1181QC'd by RTI0
Inactive0-7.78970.80.3897-2-17.425340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-11.4437-14.023-15.1485-15.88081.8136-13.5013-8.13622.80881.5308-16.02122.2517-5.7850.4858-11.4437QC'd by RTI0
Inactive04-10.42311.28533.5569-3.1220.92258.3539-5.9784-6.6058-9.2911-3.1787-3.4870.71291.4318-10.4231QC'd by RTI0
Inactive0-7.73824.95490.30320.011512.211240 0 0 0 0 0 0 0 0 0 0 0 0 0 11.52880.950616.703814.1576-2.5052-1.4079-7.1617-2.59110.2899-1.46337.03017.09990.33931.5288QC'd by RTI0
Inactive0-8.54990.80.6938-2.94661840 0 1 0 0 0 0 0 0 0 0 0 0 0 0-4.125112.009133.24450.68950.67250.2088-2.7945-1.4329-3.4616-5.9923-1.3187-2.4253-0.3401-4.1251QC'd by RTI0
Inactive04-0.8939-2.9136-1.9824-0.2399-1.3445-0.37655.8516-2.01614.2702-3.190856.3924-0.94610.5242-0.8939QC'd by RTI0
Inactive04-8.7412-6.5753-17.70663.7172-10.82516.8532-5.6494-1.0518-7.7844-4.0289-6.4104-4.9608-14.2816-8.7412QC'd by RTI0
Inactive04-8.43490.6625-12.86764.0735-4.892734.2082-7.0634-7.0056-4.6588-0.7159-10.6746-6.22913.8264-8.4349QC'd by RTI0
Inactive04-8.0905-8.9909-7.30310.6324-11.7986-17.7946-11.0081-10.6951-13.728-15.7973-13.7019-0.8883-7.3389-8.0905QC'd by RTI0
Inactive047.7339-3.1519-12.65715.9451-3.8215-9.616611.4708-10.59340.5021-4.2503-7.881-10.49670.61947.7339QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV208
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive042.8556-6.3304-0.7647-8.8733-1.31120.8858-0.7954-2.57631.03362.1512-9.58190.21270.5852.8556QC'd by SIGMA0
Inactive04-7.8426-4.3078-16.60170.242-13.2719-11.6752-0.79161.95570.8861-16.7872-2.3074-10.3741-2.8885-7.8426QC'd by SIGMA0
Inactive0-4.21014.95490.4665320.65440 0 0 0 0 0 0 0 0 0 0 0 0 0 025.3647-1.024-9.455-4.84037.0107-0.83190.7153-0.51971.3173-2.122121.3-1.94980.638125.3647QC'd by SIGMA0
Activator10.9622354.094588Complete curve; high efficacy-4.96011.88510.9871350.4672-3.62731.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0308.1942-1.3985-5.089-0.241-8.8635-0.459-5.64280.57321.391323.285681.7578248.9758341.586308.1942QC'd by SIGMA0
Inactive0-4.21034.95490.404514-0.05940 0 0 0 0 0 0 0 0 0 0 0 0 0 011.96942.92772.7682-4.33181.2545-0.3862.9265-3.3749-0.10960.69872.85880.883-6.299211.9694QC'd by SIGMA0
Inactive04-13.0353-2.27130.1463-3.5651-12.8612-3.9456-7.20940.7903-1.74652.1902-4.8911-11.17319.074-13.0353QC'd by Enamine0
Inactive0-4.66014.95490.572422-4.384840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.1612.5163-10.0126-10.1585-10.3418-5.59460.93372.7621-4.0144-12.8206-6.8537-0.243720.2317-3.161QC'd by Acros0
Inactive04-7.4276-3.9949-3.4557-6.7725-8.6378-3.7241-4.4626-9.5948-6.0438-0.4032-7.51030.5018-6.0984-7.4276QC'd by SIGMA0
Activator54.941165.51310Single point of activity-4.26014.95490.9754156.7033-8.809730 0 0 0 0 0 1 0 0 0 0 1 0 0 0131.9051-3.0176-7.8198-5.984-12.7666-12.3564212.7294-11.8023-3.2899-12.078168.6093-7.3461-9.2414131.9051QC'd by LightBiologicals0
Activator21.8724188.631741Partial curve; high efficacy-4.66012.63840.9884181.566-7.06562.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0189.1313-6.8974-9.5309-15.2558-4.7097-9.1661-13.1889-0.3751-4.4697-4.7565-3.896451.8043130.9924189.1313QC'd by SIGMA0
Inactive0-4.46011.210.5164-15.5464-141 0 0 0 0 0 0 0 0 0 0 0 0 0 0-12.955414.77360.1105-0.3273-0.6686-1.19261.6937-0.1163-2.6784-9.52550.8128-1.5346-10.5306-12.9554QC'd by SIGMA0
Inactive0-4.21014.95490.465-22.3147-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.92891.2242-10.46842.60172.96771.2054-1.31262.3634-4.18770.0322-1.4713-0.911-0.8096-16.9289QC'd by Enamine0
Inactive044.45532.40422.23260.41450.24591.92160.4022-0.87521.5279-1.3064-0.98321.2208-0.59624.4553QC'd by LightBiologicals0
Inactive040.31653.88260.36471.64325.15721.7629-7.38692.44130.0071-1.3988-7.01262.4097-0.29750.3165QC'd by SIGMA0
Inactive04-1.8527-6.04173.3136-21.7204-0.80272.34064.71844.32133.25283.59745.3302-0.15211.3023-1.8527QC'd by SIGMA0
Activator3.8895232.94451Partial curve; high efficacy-5.41011.47870.9923230.9277-2.01642.10 0 0 0 0 0 0 0 0 0 0 0 0 1 162.38620.4013-5.072-0.61550.58821.3374-1.29933.258221.944396.8738157.7951204.7231124.904862.3862QC'd by SIGMA0
Inactive04-3.47891.4151-13.25430.1998-1.77564.16140.810614.65013.76140.68722.5933-0.70390.494-3.4789QC'd by ChemService0
Inactive0-5.36014.95490.3211-5.731040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-6.73460.55414.9704-5.8731-0.6018-6.8821-1.45694.11891.88980.1337-7.25430.1379-8.5259-6.7346QC'd by SIGMA0
Inactive040.0083-0.6469-9.92481.92781.2911-0.062-5.6651-3.0476-0.16126.3388-7.89081.4553-6.56660.0083QC'd by SIGMA0
Inactive0-7.61014.95490.3777-1.7299640 0 0 0 0 0 0 0 1 0 0 0 0 0 01.83795.69061.496510.08612.0512-2.1055-0.94551.516621.5335-14.3582-0.32220.0976-0.37391.8379QC'd by ChemService0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV378
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-4.9327-8.7446-7.1163-2.5925-13.0435-1.7843-2.484-3.6729-7.613-0.8889-4.8878-7.5645-0.6005-4.9327QC'd by SIGMA0
Inactive04-16.415-8.5001-2.0629-19.3599-6.5839-1.4707-9.8236-3.5022-4.2079-3.24190.1219-5.8248-9.6459-16.415QC'd by SIGMA0
Inactive04-10.7413-7.39220-0.2838-0.5653-4.5221-3.0423-6.7941-2.6028-14.553-0.3935-3.6205-12.0068-10.7413QC'd by SIGMA0
Inactive043.2663.16150.08866.5708-1.32983.14050.67442.5665-6.09993.2181.004916.1034.23573.266QC'd by SIGMA0
Cytotoxic54.799939.068320Single point of activity-4.26124.95490.6959-38.67160.3967-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.39179.59144.3283-0.759-4.06415.535-4.0123-9.3196-1.0468-1.3955-5.42130.0991-1.6536-32.3917QC'd by SIGMA0
Inactive04-5.73092.4973-8.6586-4.0186-3.069512.231313.719.8546-5.47310.4059-3.83138.4712.9818-5.7309QC'd by SIGMA0
Inactive0-7.05671.96730.5185-1.2735.540 0 0 0 0 0 0 0 0 0 0 0 0 0 110.3592.8275.80910.02684.8573.60620.9278-1.1672-0.7265-0.7966-6.4775-0.77652.138810.359QC'd by SIGMA0
Inactive0-8.01492.33320.3168-1.860140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.70960.2868-5.71687.12927.41961.630516.89211.03154.11626.683716.156210.6194.529213.7096QC'd by SIGMA0
Inactive0418.46045.7588.027-2.207411.8158-1.23930.152411.417911.842511.9427.8774-0.79384.7718.4604QC'd by SIGMA0
Inactive04-3.1832-3.0169-21.80232.0915-0.17060.85444.67233.83911.6775-3.1957-4.5826-1.7625.6197-3.1832QC'd by SIGMA0
Inactive047.06459.82295.06560.6911-2.4601-2.9394-0.43582.99575.00434.57664.344910.4285.47957.0645QC'd by SIGMA0
Inactive042.87990.629-10.63982.0031-0.51151.142-1.08143.68224.59776.9657-0.74484.399614.49732.8799QC'd by SIGMA0
Inactive041.50152.66799.95341.34317.349517.04560.9676-3.3756-0.89150.99653.49348.230615.41721.5015QC'd by SIGMA0
Inactive04-4.07418.0515-9.6192-9.13193.341-15.15631.344611.16750.4706-5.54756.1638-8.9391.0036-4.0741QC'd by SIGMA0
Inactive0419.28391.7535-1.83222.628214.76662.45912.84031.7826-3.637912.539-0.274713.7515-2.088619.2839QC'd by SIGMA0
Inactive04-6.837-4.13767.35992.9047-1.07680.16948.3141.13760.9196-7.8482-6.9238-0.58641.4242-6.837QC'd by SIGMA0
Inactive0-5.70660.70.566221.939140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.1135-1.102106.448313.25958.79225.6758-3.3848.396913.63420.653922.032513.87680.1135QC'd by SIGMA0
Inactive049.5114.849813.2582.0698-2.30842.241823.650616.2267-0.179922.16161.8408-0.3677-0.42029.511QC'd by SIGMA0
Inactive0-4.24844.95490.446625-0.037740 0 0 0 0 0 0 0 0 0 0 0 0 0 020.76270.901-2.66373.17736.35525.97582.4992-2.72392.61-0.87970.7471-17.94812.574120.7627QC'd by SIGMA0
Inactive04-10.2166-8.0741-1.4322-10.2813-2.02430.8873-4.2479-4.2814-3.429-4.25980.2946-0.0902-2.3971-10.2166QC'd by TCI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV365
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator8.485286.606643Partial curve; high efficacy-5.07132.40640.976389.16782.56122.10 0 0 0 0 0 0 0 0 0 0 0 0 1 086.90821.02660.05454.52680.01668.86952.65560.78571.9848-1.729210.014540.5982151.254986.9082QC'd by Vitas0
Inactive0-5.57134.95490.677913.5-8.357740 0 0 0 0 0 0 0 0 0 0 0 0 0 017.6815-0.32180-6.2613-9.9352-14.3533-14.1175-8.9264-13.9610.3022-4.10819.06623.313517.6815QC'd by GVK0
Inactive042.646-6.42590-4.1621.831-8.0314-4.78624.5388-12.654-4.28110.969-4.2381-0.15752.646QC'd by GVK0
Inactive0-8.72132.72020.4352-2-14.028340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-14.1844-14.6069-10.5571-3.5931-0.24434.3078-13.0836-0.4989-10.2984-1.20991.2966-1.1947-0.2081-14.1844QC'd by SIGMA0
Inactive04-3.475505.507-0.7209-2.3493.63873.73590.8937.34436.5535-1.6209-3.779416.6908-3.4755QC'd by Vitas0
Inactive0-4.67131.44870.475420-1.214840 0 0 0 0 0 0 0 0 0 0 0 0 0 014.54470-12.2623-0.7698-7.24351.02327.2280.10374.4052-0.963-0.62993.19686.097214.5447QC'd by GVK0
Activator26.832592.231910Single point of activity-4.57134.95490.894483.3113-8.920630 0 0 0 0 0 0 0 0 0 0 0 0 0 075.0566-10.44290-9.88480.1396-10.1825-9.9995-17.11032.4671-2.7879-10.8915-23.1147-5.328475.0566QC'd by GVK0
Inactive0-8.17134.95490.3427-3.1739340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.58472.37223.77442.3601-8.612-3.4854-2.7786-8.8949-7.2433-2.8949-2.4933-0.32235.0376-0.5847QC'd by Bosche0
Inactive0-5.67134.95490.4487-12.8572140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.593504.65213.2642-5.54511.15910.7332-1.1835-1.49942.4658-8.72362.9154-21.5477-0.5935QC'd by GVK0
Inactive048.81960-0.4241-1.8954-7.95630.5962-8.24726.0735-0.25930.7421-0.1487-2.9588-0.70858.8196QC'd by GVK0
Inactive04-0.0567-1.1379-12.553-7.81915.4588-10.82372.7893.17920.9157-0.642-9.1488-4.9765-9.6703-0.0567QC'd by GVK0
Inhibitor16.930146.90560Single point of activity-4.77131.10.5088-48.2775-1.3719-30 0 0 0 0 0 0 0 0 0 0 0 0 0 1-23.03270-0.6207-0.43857.14511.3083-0.19720.1005-14.869-12.0261-6.8573-0.2305-36.5738-23.0327QC'd by GVK0
Inactive04-19.84640-2.6054-13.7849-2.4577-5.7211-16.7659-10.3853-0.7293-3.0864-6.492-5.1247-16.5498-19.8464QC'd by Microsource0
Inactive04-16.345400.27621.67361.0416-0.26852.6855-19.9410.7119-13.46282.0044-4.5615-2.2088-16.3454QC'd by GVK0
Inactive0-5.42131.37230.39735-8.83940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-10.4536-19.86580-10.924-9.1864-6.1797-0.4783-11.1336-11.2034-11.5766-2.38671.11013.7454-10.4536QC'd by GVK0
Inactive04-9.39580-15.25711.24530.13414.95650.82550.2492.19480.29451.70286.08761.8921-9.3958QC'd by GVK0
Inactive0-4.97133.990.6676-22.85242.540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.38073.96586.37570.71051.94388.3116-5.8821-7.17957.95175.79273.7389-1.6269-24.04370.3807QC'd by GVK0
Inactive04-15.7547-16.86130-0.9266-9.3733-1.5706-13.3964-10.692-0.2257-0.0563-16.54230.9534-15.7303-15.7547QC'd by Tocris0
Inactive04-1.84144.3389-3.50071.7649-15.66832.00261.42850.8835-5.8273.40023.368148.89163.8973-1.8414QC'd by GVK0
Inactive043.5266-8.2360-1.899813.78435.228413.5915-3.3487-0.21965.29895.1035-0.14670.7463.5266QC'd by GVK0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV822
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic8.485243.048321Partial curve; partial efficacy-5.07132.35310.8574-38.89694.1515-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-40.78545.2831-0.16240.02640.99280.74150.9842-2.518910.176216.18536.2409-17.4861-26.8257-40.7854QC'd by Microsource0
Inactive0-7.62133.06540.48067.5-2.760240 0 0 0 0 0 0 0 0 0 0 0 0 0 09.8114-0.9727-4.8469-2.6345-0.84613.14139.363-2.604112.50013.610410.192913.01110.00269.8114QC'd by Selleck0
Cytotoxic9.520586.722142Partial curve; high efficacy-5.02131.75290.9689-85.47251.2496-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-89.03383.36492.4659-0.68964.1315-0.81468.47012.1755-7.08250.0244-7.2368-31.3673-56.5649-89.0338QC'd by Microsource0
Inactive041.93340.41322.1328-1.066.91535.40546.77751.1052-4.4176-32.2423.65730.28429.20631.9334QC'd by SIGMA0
Cytotoxic16.930149.723321Partial curve; partial efficacy-4.77132.40640.8642-49.8188-0.0955-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-43.80211.124-0.4846-0.12142.51935.40014.2115-0.145-1.7743-12.87050.9978-6.6548-25.0298-43.8021QC'd by Microsource0
Inactive040.683-6.0203-3.0276-0.4228-0.6535-0.283-0.7135-0.9467-5.0249-0.5891-7.1629-10.3891-2.11390.683QC'd by Labotest0
Inactive04-7.88634.66455.187-0.83962.96212.4404-5.26055.43432.5966-3.7984-1.85873.35973.0908-7.8863QC'd by SIGMA0
Inactive0-4.52134.95490.5144-19.936-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.6133-4.90210.2671-1.1373-1.15194.0221-2.8879-1.5786-7.5865-4.8278-2.60048.0241-0.7001-16.6133QC'd by Microsource0
Inactive0-6.32134.95490.377-3.5899540 0 0 0 0 0 0 0 0 0 0 0 0 0 110.25151.027710.59696.15660.8041-0.23631.03779.82677.8327-6.84410.3465-10.90820.083110.2515QC'd by Vitas0
Inactive042.26870.07791.88060.76273.75511.5221-1.36212.4817-1.4475-14.386-5.7175-5.3274.762.2687QC'd by Labotest0
Cytotoxic4.252751.912722Complete curve; partial efficacy-5.37131.62660.9453-50.91390.9987-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.60345.0384-4.89210.0860.27024.4697-0.48647.16770.4012-2.2223-14.1412-35.4965-52.845-39.6034QC'd by Specs0
Inactive043.287913.20085.99150.5737-0.10155.9296.2916-7.1749-0.74236.17374.413717.98546.41423.2879QC'd by Specs0
Inactive0413.007-4.9949-0.0285.0288-0.542-4.44245.59557.37523.9094-14.83655.1595-1.9929-0.39713.007QC'd by Labotest0
Inactive040.12657.25313.79420.7983.45041.67535.36611.05630.3063-17.30017.0679-3.8381.71970.1265QC'd by Labotest0
Inactive042.7567-1.3486-0.00990.73422.55193.1976-2.524-0.3468-9.6554-2.0931.0802-7.75972.95282.7567QC'd by SIGMA0
Inactive040.82523.12132.30920.0513.4197-0.9374-2.4367-1.9651-1.86492.46166.8884-3.55262.03030.8252QC'd by Specs0
Inactive0412.82342.4425-0.44610.43694.86624.188510.4156-0.0871-0.697-3.82816.2664.859211.104912.8234QC'd by Microsource0
Inactive04-0.593910.4617-0.31641.75264.5012-1.244511.50844.7483-7.8273-15.77046.2867-11.03125.8757-0.5939QC'd by SIGMA0
Inactive0-9.22134.95490.3854-0.54251440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.969610.213-0.2751.2734-1.8998-0.71614.12091.13-0.0525-0.18393.4979-7.5354-3.7917-3.9696QC'd by Labotest0
Inactive042.9699-3.79022.1807-1.7828-0.88182.4962-2.6747-1.75432.2139-3.24690.6907-10.07222.27182.9699QC'd by Vitas0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV159
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.86410.80.3875131.048140 0 0 0 0 0 0 0 0 0 0 0 0 0 08.45341.2371-0.31680.2815-0.578510.0845-0.7819-3.70995.6634-0.2285.90985.358212.5448.4534QC'd by SIGMA0
Inactive0-8.90214.95490.47680-14.237440 0 0 0 0 0 0 0 0 0 0 0 0 0 05.3106-3.9679-0.9064-0.1971-0.8477-4.1457-0.99771.62460.0931-1.33841.2572-0.6955-4.80345.3106QC'd by SigmaAldrich0
Inactive041.02930.32712.1540.4664-2.179-1.40230.14798.66543.41155.92726.5917-8.36457.96631.0293QC'd by SigmaAldrich0
Inactive0-5.55890.20.327514-13.037440 0 0 0 0 0 0 0 0 0 0 0 0 0 00.1893-5.3527-18.3645-3.3463-3.6483.8982-10.3569-1.041-2.317-3.35086.8459-3.103313.54620.1893QC'd by SigmaAldrich0
Inactive0-5.6994.95490.41515.5-1.280440 0 0 0 0 0 0 0 0 0 0 0 0 0 1-3.4673-3.909-1.8456.07946.6348-2.5062-1.5818-3.8038-2.42534.67185.27866.29415.0596-3.4673QC'd by SigmaAldrich0
Inactive040.5688-4.1372-0.3967-1.5611-3.285-1.1585-0.018710.4505-2.9705-0.3053-0.0983-7.1629-1.33140.5688QC'd by SigmaAldrich0
Inactive0-4.2094.95490.3908-17.7069-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.50574.8097-1.6942-1.3834-7.5388-1.7719-1.2029-0.35810.901-1.4353-4.5824-3.66553.1971-13.5057QC'd by SIGMA0
Inactive04-1.27973.5207-2.49483.96232.6849-1.5310.8881-10.4751-1.28212.18786.4139-2.49510.2085-1.2797QC'd by SIGMA0
Inactive041.0283-0.4756-12.3001-5.5103-0.1743-2.6256-11.4404-11.6686.2351-2.2512-5.1080.7848-7.34241.0283QC'd by SIGMA0
Inactive040.94320.75940.988318.962614.29172.15132.42865.69981.2613-2.7951.06240.2146-0.08770.9432QC'd by SIGMA0
Inactive049.853413.81771.538511.23119.684-0.0199-6.0352-4.37145.66948.41082.47796.4969-0.04439.8534QC'd by SIGMA0
Inactive0-4.21124.95490.3412-21.4496140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.2083.68444.35545.11454.10112.6662-13.7864-12.28431.06224.32628.4508-1.3872-0.1594-16.208QC'd by Research Biochemical0
Inactive04-19.3036-0.62070.8664-0.571912.3734-3.2162-22.2356-24.4009-8.45971.4920.108-2.53653.6237-19.3036QC'd by SigmaAldrich0
Inactive044.475-0.0376-1.2614-13.0749-2.47974.008-1.9292-25.97930.848-3.96914.06111.21292.53564.475QC'd by SIGMA0
Inactive0-5.25624.95490.6306-16.9047-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.92063.868-2.4948-1.9864-2.15751.4413-8.4707-9.35272.34873.2139-14.7451-14.2038-10.519-24.9206QC'd by ChromaDex0
Inactive0-5.30964.95490.7023-20.9197040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-19.63411.55125.2906-0.74095.3658-4.31030.1166-18.17714.309-0.0902-18.3205-24.9331-17.6239-19.6341QC'd by SIGMA0
Inactive041.0091-0.61491.64853.05532.21034.3448-0.1307-22.67423.64670.6253-1.0888-7.05951.12483.23981.0091QC'd by SigmaAldrich0
Inactive0-4.8082.35310.425623.5-2.20840 0 0 0 0 0 0 0 0 0 0 0 0 0 17.46058.2789-2.64731.954-0.8692-2.1201-19.34-16.0592-1.36042.0296-0.129110.618819.86147.4605QC'd by Sensient0
Inactive0-5.06711.47810.789718-3.291540 0 0 0 0 0 0 0 0 0 0 0 0 0 14.8784-2.903-3.31612.663-3.8778-2.2076-9.4096-6.5877-2.42054.94120.956515.029214.83874.8784QC'd by Pfaltz-Bauer0
Inactive040.898-5.144-4.4883-2.145-3.463110.3215-3.9271-11.130.5937-1.5597-0.85449.81064.98280.898QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV202
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-7.3758-0.7877-3.27010.0141.7013-7.8748-5.1827-6.2686-5.1561-9.3082-7.68583.5929-10.2498-7.3758QC'd by SIGMA0
Activator38.895279.901140Partial curve; high efficacy-4.41011.62590.919479.0967-0.80442.10 0 0 0 0 0 0 0 0 0 0 0 0 0 062.62023.40484.07381.00250.2637-12.7877-4.81713.4033-2.5478-3.68727.384317.327728.845262.6202QC'd by Sigma DiscoveryCPR0
Inactive0-4.21014.95490.481218-2.238940 0 0 0 0 0 0 0 0 0 0 0 0 0 013.0644-0.5726-5.79248.04180.172-2.137-4.1871-4.2849-3.8138-3.3394-1.6984-3.5829-1.391613.0644QC'd by MP Biomedicals0
Inactive040.85863.7707-5.1242-1.77548.6578-1.36621.28759.5889-0.6112-3.13740.2344-0.1463-0.03380.8586QC'd by SIGMA0
Inactive0-4.66034.95490.45164-2.444840 0 0 0 0 0 0 0 0 0 0 0 0 0 03.5724-2.3541-3.77710.1128-3.6013-0.1967-4.8326-4.4902-3.261-4.743.4-3.36754.87433.5724QC'd by SIGMA0
Inactive04-1.5792-2.9775-0.3082-0.04085.552-3.0376-2.12742.9081-0.972.5571.60563.5688-2.1154-1.5792QC'd by SIGMA0
Inactive04-3.24114.6629-9.8321-1.2555-0.62083.887637.4278-0.7186-1.7803-2.6711-0.3958-5.13894.204-6.6116-3.2411QC'd by LightBiologicals0
Inactive04-5.77253.35435.5606-2.5150.74692.54313.08292.51132.94125.8043-4.1459-2.9981.1272-5.7725QC'd by SIGMA0
Inactive049.3453-3.0587-4.72780.6755-8.6618-3.6004-5.1899-2.69986.02765.8959-5.73-4.471-6.03629.3453QC'd by LightBiologicals0
Inactive0-5.91010.60.3202-6.93283.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.1107-1.853713.76847.1434-1.18787.8068-5.8411-1.82650.1382-2.5712-4.2462-5.6582-1.5684-9.1107QC'd by LightBiologicals0
Inactive04-7.2151-1.72950.43414.99610.2796-7.5367-0.33556.84274.6981-5.72771.09072.29352.3957-7.2151QC'd by SIGMA0
Inactive0-4.310110.4216-20.0887440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.40725.66480.2326.04583.2443-4.77913.9750.174910.9938-0.8349-1.3601-4.90460.5697-13.4072QC'd by SIGMA0
Inactive040.6747-1.30960.7316-5.2078-1.4784-6.1707-6.31822.1785-3.7947-1.0003-9.8199-1.578-8.40360.6747QC'd by SIGMA0
Inactive04-12.0085-4.09926.0584-9.4685-6.9633-2.2557-10.5533-7.35350.0130.1836-5.8167-9.1387-9.2296-12.0085QC'd by LightBiologicals0
Inactive0-5.41014.95490.39786-0.856140 0 0 0 0 0 0 0 0 0 0 0 0 0 011.49650.531.2909-1.7803-2.687-3.21340.3726-1.76910.7235-1.336912.57980.61090.089411.4965QC'd by SIGMA0
Inactive04-1.4682-5.3624-8.5522.0405-7.7996-0.1045.64176.60932.2753-11.41981.35823.17015.317-1.4682QC'd by SIGMA0
Inactive04-1.9548-0.3469-4.1930.233-2.7259-4.12371.5867-4.0101-1.589-0.0441-3.4171-9.53152.4248-1.9548QC'd by ChemService0
Inactive0-7.76014.95490.4769-5.914-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.1452-1.6157-1.51762.4522-6.9585-1.8215-10.345-6.1183-4.7003-5.1159-3.3985-10.2328-7.53292.1452QC'd by SIGMA0
Inactive0-4.3144.95490.551329-1.795440 0 0 0 0 0 0 0 0 0 0 0 0 0 026.0201-3.9988-3.4143-3.1105-5.653-9.4128-0.3653-2.86348.1995-0.4057-2.051-1.87522.884326.0201QC'd by EPA0
Inactive04-9.717-7.55361.8624-10.8397-5.44331.22650.7592-7.2226-7.1647-0.1417-7.8421-2.1024-1.104-9.717QC'd by Crescent0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV689
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Cytotoxic55.66169.607241Partial curve; partial efficacy-4.25443.24750.9645-71.0973-1.4902-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-53.86160.84590.21760.4959-3.3673-7.9542-0.4850.87850.2602-5.05280.0844-4.8395-13.5588-53.8616QC'd by LKT Lab0
Inactive0-4.87270.60.4492-17.2481-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.9129-0.8708-0.9932-0.10140.8045-5.952-6.14190.26580.39880.1889-9.0811-0.5996-14.3735-10.9129QC'd by SIGMA0
Inactive0-5.07054.95490.3261-5.4821040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.688-1.99182.4151-1.2712.27-2.15421.3835-0.02690.05581.7737-1.9944-1.9489-7.4851-3.688QC'd by TCI0
Cytotoxic21.826933.994620Partial curve; partial efficacy-4.6611.75290.8595-35.9946-2-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-35.2888-1.1158-0.2481-0.8283-1.2075-4.79370.1012-5.5396-6.2014-0.1408-0.218-21.4998-19.1186-35.2888QC'd by SIGMA0
Inactive0-5.25394.95490.7479-11.0575-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.3280.3836-1.04820.81271.5291-7.0143-0.1714-0.27880.530.2131-0.4784-10.2064-13.3812-8.328QC'd by SIGMA0
Cytotoxic55.9441106.675320Single point of activity-4.25224.95490.9863-107.4649-0.7896-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-90.0041-0.1260.08581.2517-0.07862.89171.29111.9346-2.42210.041-1.1903-8.6058-9.9229-90.0041QC'd by SIGMA0
Inactive00040.02360.1055-0.2139-0.4297-0.4957-10.1401-1.2193-6.2121-2.65490.1198-1.2053-0.44750.05790.0236QC'd by SIGMA0
Inactive0-5.07244.95490.6859-14.4467-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.80170.13851.62530.6342-0.9523-1.91720.7988-10.21540.48713.33980.9245-6.413-17.8723-10.8017QC'd by SIGMA0
Inactive00042.02441.42183.16263.0023-0.4824-1.93081.39912.14280.549-13.883-0.379-2.92421.7412.0244QC'd by SIGMA0
Inactive0-4.61251.85790.8312-22.61371.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-23.84471.1503-0.74640.39311.16184.67261.93011.81551.74520.60135.3411-12.0389-8.7286-23.8447QC'd by SIGMA0
Inactive0004-3.4271-0.3776-0.65160.0179-0.282-0.8236-0.26560.06060.1454-0.038-0.2845-2.6228-3.2934-3.4271QC'd by SigmaAldrich0
Inactive0-4.36413.1320.7553-19.8489040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.9574-0.35731.30171.27941.83152.6845-0.9184-2.10761.877-8.15250.66380.7179-6.8277-16.9574QC'd by SigmaAldrich0
Inactive0-4.84980.90.4941-20.5874-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.4895-0.06681.3428-2.82980.6418-9.4205-6.8736-9.5814-0.3393-2.6082-0.2259-12.6383-12.3502-15.4895QC'd by ChromaDex0
Inactive00041.29060.47550.41140.1566-5.70441.73831.15671.4254-0.6115-3.4652-1.48130.36221.46221.2906QC'd by SIGMA0
Inactive00041.1901-0.2219-1.1968-3.4803-0.2969-4.40061.31262.89211.22671.1129-2.67862.3447-2.48061.1901QC'd by SIGMA0
Inactive0004-0.32953.38480.49230.807-1.393-1.3621.21123.57983.0263-0.9962-0.91862.34311.8549-0.3295QC'd by SigmaAldrich0
Inactive00043.4046-0.9813-0.2358-0.4965-0.0873-0.1523-2.4317-1.2237-0.7157-2.6104-4.09132.0322-5.73393.4046QC'd by SIGMA0
Inactive0004-1.80820.72851.32342.6709-4.3133-0.8979-0.63640.1574-2.29363.81920.2489-2.08541.7416-1.8082QC'd by SigmaAldrich0
Inactive0-4.70871.28760.8517-17.6909040 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.7424-0.1759-0.9468-0.7564-0.056-0.56420.1765-0.33072.2008-6.7251-1.8381-5.6854-13.4326-14.7424QC'd by SigmaAldrich0
Inactive00043.0880.9806-0.0673.7852-0.37390.58322.31010.15290.05232.1308-0.21190.1292-0.50213.088QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV894
Protocol: Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-2.6026-1.7975.89993.0748-15.192-5.1959-4.64860.07135.84590.242-2.4397-10.3851-7.7055-2.6026QC'd by ACC0
Inactive0-5.62134.95490.5983-13.8026-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-15.03940.7082-7.1062-6.45310.9924-5.73244.95740.5469-0.5803-0.1158-7.0559-15.2522-9.1362-15.0394QC'd by ACC0
Activator18.99591238.497154Partial curve; high efficacy-4.72131.55790.98671257.124618.62752.10 0 0 0 0 0 0 0 0 0 0 0 0 0 01002.4917-0.6422-1.2054-0.772550.264311.645820.54550.93771.224928.1656124.6638254.3234546.90561002.4917QC'd by ACC0
Inactive0-8.47131.88510.4864-2.15241940 0 0 0 0 0 0 0 0 0 0 0 0 0 00.048923.86114.4099.31771.26670.7891-11.6442-12.6270.8718-4.89584.29410.52630.98980.0489QC'd by ACC0
Inactive0-5.63624.95490.3755-0.5-9.203940 0 0 0 0 0 0 1 0 0 0 0 0 0 02.2375-5.0601-12.9044-13.83432.6465-9.2201-8.212832.5557-12.3972-9.49852.865-6.5312-2.82972.2375QC'd by RTI0
Inactive04-1.28022.6074-15.4650.13821.22230.25050.94971.3356-4.3854-11.9115-1.47821.7501-12.7348-1.2802QC'd by RTI0
Inactive04-5.325610.342617.61940.57120.0244-3.26097.5111-2.0198-8.749311.648117.2377-0.455818.491-5.3256QC'd by RTI0
Inactive04-2.2429-0.615848.25450.97410.68273.19743.0502-8.7061-3.674-0.16290.075913.3073-1.0945-2.2429QC'd by RTI0
Inactive04-10.35541.94890.3345-14.3205-1.785337.5999-0.361-5.6006-0.37440.41158.77745.61790.9142-10.3554QC'd by RTI0
Inactive04-1.5991-9.4569-0.1528-3.1449-1.0509-3.54640.99950.947118.9556-1.61920.3341-1.49712.0468-1.5991QC'd by RTI0
Inactive0-4.7754.44950.37865-0.875740 0 0 0 0 0 0 0 0 0 0 0 0 0 05.47123.7148-0.2315-2.9791-1.7564-6.14641.665-3.30124.05251.3643-0.99013.8074.38075.4712QC'd by RTI0
Inactive040.19390.2492-7.583-8.0028.06760.7863-0.734212.71667.5465-8.7219-0.40080.250716.35730.1939QC'd by RTI0
Activator62.154950.921210Single point of activity-4.20654.95490.801951.65950.738330 0 0 0 0 0 0 0 0 0 0 0 0 0 042.82937.78174.8067-6.8947-0.39036.5057-2.03177.1248-10.4951-2.5023-2.07493.7113.790842.8293QC'd by RTI0
Inactive0-7.73824.95490.3412-3.3808740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.1951-4.33049.738914.0226-11.5674-5.2995-4.6299-9.9209-0.6342-3.21060.26890.5118-0.5797-0.1951QC'd by RTI0
Inactive0-7.94991.59360.5942-10.86451.540 0 1 0 0 0 0 0 0 0 0 0 0 0 0-13.27140.675922.1412-5.3008-7.8279-10.7766-9.9332-7.8001-13.4679-12.9848-9.7006-10.3588-7.1505-13.2714QC'd by RTI0
Inactive041.08380.07883.7298-2.0071-1.5681-0.18352.2990.5113.6746-1.301160.652-2.0522.57431.0838QC'd by RTI0
Inactive04-3.5534-7.9896-16.56040.5208-13.160.2883-3.32820.5396-5.1164-2.8324-5.6343-5.7751-14.1456-3.5534QC'd by RTI0
Inactive04-13.063930.2518-12.6791-0.5123-9.208519.9477-13.359-9.2717-7.6776-1.8805-11.0769-9.41010.5771-13.0639QC'd by RTI0
Inactive04-4.5943-4.76663.0544-2.0187-6.4339-21.249-8.7037-9.3713-16.543-13.2255-7.6803-1.6375-4.5606-4.5943QC'd by RTI0
Inactive044.6366-6.1501-14.813311.0008-9.6366-12.26414.5909-10.3186-0.1834-8.2404-12.8158-19.41014.14224.6366QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV102
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Activator48.5771245.234742Partial curve; high efficacy-4.31363.19250.9861244.2224-1.01232.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0197.59092.79990.1145-10.14374.44932.4614-6.04860.71051.36361.1909-17.903610.344856.546197.5909QC'd by Io-li-tec0
Inactive040.921-4.522-0.41033.610311.30590.77741.770816.4277-1.92156.19158.88380.14372.33590.921QC'd by Io-li-tec0
Inactive0410.36171.98465.86320.691513.9728-8.2141.7669-1.733410.36541.9563-16.2694-0.96155.587710.3617QC'd by Io-li-tec0
Inactive0419.11891.42224.2838-10.202618.81053.85119.9584-0.26199.97270.63275.67220.66851.733219.1189QC'd by Io-li-tec0
Inactive044.9626-0.51480.2643-2.48815.4682-2.6876-2.17884.222-2.94051.89871.08380.04550.50564.9626QC'd by Io-li-tec0
Inactive040.666615.237712.80390.573-4.6041-6.116828.7912.07083.966632.36930.0564-4.3988-7.34960.6666QC'd by Io-li-tec0
Inactive0414.473616.574547.836113.5522-0.505110.7274-1.01738.43479.27983.03456.2718-1.6326-0.845314.4736QC'd by Io-li-tec0
Inactive04-10.93880.9715-19.86310.618967.7971-3.03722.85650.89670.377-13.56010.29383.74670.5731-10.9388QC'd by Io-li-tec0
Inactive04-9.69010.69590.797410.37719.1637-0.28360.280360.29770.4062-7.7797-2.510311.50868.7765-9.6901QC'd by Io-li-tec0
Activator34.9795186.5640Partial curve; high efficacy-4.45622.25260.9257192.51965.95972.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0165.39490.27068.518211.26572.124510.91211.902349.02480.52182.29820.913220.0771102.9932165.3949QC'd by Io-li-tec0
Activator49.098218.583142Partial curve; high efficacy-4.30892.84730.9843221.91493.33182.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0175.28820.122813.9777-4.7243.8828-0.35-0.285-4.71078.6067-0.45376.478419.520557.0117175.2882QC'd by Io-li-tec0
Inactive04-0.3737-1.107-9.668117.595-6.9267-10.3374-12.3277-2.1882.4052-1.17882.22392.617411.879-0.3737QC'd by Io-li-tec0
Inactive043.4616-8.92793.13720.14691.52971.278918.8175-8.2727-0.19259.8072-6.48620.9155-0.52463.4616QC'd by Io-li-tec0
Inactive048.563713.5480.34699.3476-2.6914.94942.018919.73492.46752.37712.427117.03134.73388.5637QC'd by Io-li-tec0
Activator27.3808159.306341Partial curve; high efficacy-4.56262.25260.9599163.01573.70942.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0160.765-5.4521-5.93864.82799.441613.8086-0.7263-2.86369.54916.077429.232924.0734109.8075160.765QC'd by Io-li-tec0
Inhibitor21.586448.50270Partial curve; partial efficacy-4.66581.80790.9014-45.57362.9292-2.21 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.655111.34760.2120.84081.3901-0.5055.73414.20017.1735-0.6014-0.3582-16.2507-25.0853-45.6551QC'd by Io-li-tec0
Inactive0-4.65634.95490.78220-2.722840 0 0 0 0 0 0 0 0 0 0 0 0 0 018.4823-8.925-3.1228-4.5617-9.0141-1.0521-3.24460.38692.29351.3176-0.1971-0.80919.541518.4823QC'd by Io-li-tec0
Inactive04-8.192713.8353-7.2564.16614.507710.2991-5.9204-7.47324.34837.52920.4548-0.419-3.3211-8.1927QC'd by Io-li-tec0
Inactive0-4.70824.95490.3819-11.45333.540 0 0 0 0 0 0 0 0 0 0 0 0 0 10.68851.95795.4750.47170.0687-0.588-1.45140.09434.75925.974216.7359-0.8378-10.37770.6885QC'd by Io-li-tec0
Activator43.7266216.690142Partial curve; high efficacy-4.35933.51170.9877217.38730.69722.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0191.6996-0.8544-4.31951.60940.8589-1.6148-2.3097-2.03138.6376-1.175410.52070.084462.886191.6996QC'd by Io-li-tec0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV139
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive043.04154.55111.35572.7957-0.44341.200111.24159.028416.754511.4820.28287.66518.56833.0415QC'd by ACC0
Inactive042.80137.59139.0495-0.62091.0747-4.732-4.46283.86437.69258.74097.95195.34411.21212.8013QC'd by ACC0
Inactive041.15981.7604-0.22671.90895.94328.72113.24918.04034.816-2.75513.51253.0534-0.94291.1598QC'd by ACC0
Inconclusive26.832532.580110Partial curve; partial efficacy; poor fit-4.57134.95490.805134.51.91992.40 0 0 0 0 0 0 0 0 0 0 0 0 0 029.8311-0.8721-1.08398.5472-0.2707-2.98341.93162.21267.42190.46931.66170.87984.811929.8311QC'd by ACC0
Inactive040.2839-2.1772-4.0697-10.3698-5.3113-1.35040.703-1.2597-2.0218-1.4166-10.3579-5.9102-1.08270.2839QC'd by RTI0
Inactive0-4.21954.95490.846226-2.667540 0 0 0 0 0 0 0 0 0 0 0 0 0 020.2771-5.47172.0152-3.5825-3.3714-1.09141.7732-4.0712-2.6175-1.0389-2.4335-3.0234-3.990720.2771QC'd by RTI0
Inactive042.2414-11.1994-4.6871-3.5437-8.6886-2.9094-5.7258-5.7803-0.8894-3.407-0.0539-8.0904-4.17942.2414QC'd by RTI0
Inactive041.9585-2.7596-1.74510.0148-4.8337-1.70010.0338-3.6923-2.34720.0595-3.2137-5.6786-0.76731.9585QC'd by RTI0
Inactive04-1.2619-3.1948-7.7788-2.6046-0.4272-3.8295-3.7003-6.42012.7058-0.646-6.679-1.5059-0.1652-1.2619QC'd by RTI0
Inactive0-6.95130.80.3266-4-15.958640 0 0 0 0 0 0 0 0 0 0 0 0 0 00.8899-9.0312-20.9319-9.595-14.744-10.8356-4.4105-14.11951.5086-6.789-7.2061-4.5666-6.5360.8899QC'd by RTI0
Inactive04-3.3095-0.48-2.8029-2.6833-1.9348-6.4255-1.2732-5.4438-2.2023-0.269-2.0488-2.7756-3.176-3.3095QC'd by RTI0
Inactive04-6.2279-5.8977-5.88853.0356-1.2895-3.4388-1.20891.3533-0.5692-3.48181.1139-4.28792.5505-6.2279QC'd by RTI0
Inconclusive24.744344.72610Partial curve; partial efficacy-4.60654.0950.940841.1917-3.53432.20 0 0 0 0 0 0 0 0 0 0 0 0 0 044.0163-2.326-0.5189-5.79-5.8514-7.0135-7.5286-1.7206-1.05-1.3436-7.19868.106230.24144.0163QC'd by RTI0
Inactive0-6.48820.60.4378-5.05590.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.2571.1563-0.0412-2.31731.01731.301-5.2474-1.2771-1.2256-3.5762-9.2133-1.5659-4.2972-2.257QC'd by RTI0
Inactive041.8503-2.824-6.66650.38150.0316-0.4001-2.9574-1.9037-1.82770.926-2.0444-2.0401-3.64381.8503QC'd by RTI0
Inactive04-8.135-1.0458-14.3819-1.9576-0.5344-0.84050.22110.9001-5.1908-0.19790.34280.5153-3.1524-8.135QC'd by RTI0
Inactive04-4.8676-3.4019-0.2134-1.9475-2.001-1.48782.1253-0.3133-0.7547-0.5741-2.5822-4.01362.2601-4.8676QC'd by RTI0
Inactive0-4.19194.95490.913620.5-1.770440 0 0 0 0 0 0 0 0 0 0 0 0 0 016.518-2.8047-0.6856-0.3257-3.5587-2.7511-3.1164-0.8354-0.54980.5051-2.3554-3.3496-0.3916.518QC'd by RTI0
Inactive041.94490.2436-4.13640.522.1437-2.00670.0618-2.57855.17036.2611-0.45921.30721.80131.9449QC'd by RTI0
Inactive04-5.4278-1.5878-1.3398-6.784-0.1498-7.6982-5.6898-6.1672-4.459-3.0497-0.3927-6.3544-4.354-5.4278QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:hypoxia-inducible factor 1 alpha subunit [Homo sapiens]
External ID: HIF177
Protocol: Please refer to other AIDs 1224846, 1224844, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the HIF-1 agonist mode assay (AID 1224846), cell viability counter screen (AID 1224844), and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Blue (460 nm) auto fluorescence outcomeSupplier
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveVitas
inactiveinactive0inactive0inactive0inactive0inactiveSpecs
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveMicrosource
inactiveinactive0inactive0inactive0inconclusive agonistinactiveSpecs
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveBosche
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveVitas
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveLightBiologicals
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveLabotest
inactiveinactive0inactive0inactive0inactive0inactiveSIGMA
inactiveinactive0inactive0inactive0inconclusive agonistinactiveLightBiologicals
inactiveinactive0inactive0inactive0inactive0inactiveLightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid stimulating hormone receptor [Homo sapiens]
External ID: TSHR992
Protocol: Please refer to AID 1224843 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities results from the TSHR agonist mode assay (AID 1224843). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)615 nm Activity615 nm Potency (uM)615 nm Efficacy (%)665 nm Activity665 nm Potency (uM)665 nm Efficacy (%)Supplier
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
inactiveinactive0inactive0inactive0GVK
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:nuclear receptor subfamily 1, group I, member 3 [Homo sapiens]
External ID: CAR220
Protocol: Please refer to other AIDs, 1224839 and 1224836, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the CAR agonist mode assay (AID 1224839) and cell viability counter screen (AID 1224836). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAgonist ActivityAgonist Potency (uM)Agonist Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist0.00491587440.5503939inactive0Selleck
active agonistactive agonist0.03904817536.02134645inactive0Tocris
active agonistactive agonist0.16353462843.96358481active agonist12.5009512284.84392708GVK
active agonistactive agonist0.33081998824.57079327inactive0Pharma
active agonistactive agonist0.50970984344.60374407inactive0SigmaAldrich
active agonistactive agonist0.53080386443.79624313active antagonist25.60161774-36.34968564Vitas
active agonistactive agonist0.55579136842.28539033active antagonist21.29340581-71.57094504Toronto Research
active agonistactive agonist0.61887186947.84406761active antagonist21.95840253-67.8152236Vitas
active agonistactive agonist0.69305867523.44734303inactive0SIGMA
active agonistactive agonist0.74978038667.57701705inactive0Sequoia
active agonistactive agonist0.80955685333.81552342inconclusive antagonist51.47314294-36.72382981SIGMA
active agonistactive agonist0.81518918436.19518688inconclusive antagonist54.48267328-47.49514551Sigma Chemical Company
active agonistactive agonist0.8741797539.64691387inactive0Bosche
active agonistactive agonist0.91962279440.41970881active antagonist3.804314335-58.83188651Vitas
active agonistactive agonist0.96885416145.67191945inactive0SIGMA
active agonistactive agonist0.99652844742.00291176inactive0SIGMA
active agonistactive agonist1.10895524839.48765734active antagonist53.48689088-61.16086801SIGMA
active agonistactive agonist1.12960101953.96975424active antagonist6.352213339-60.65508981SIGMA
active agonistactive agonist1.26743318965.48694129inactive0LightBiologicals
active agonistactive agonist1.28312039740.37685492inactive0Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:nuclear receptor subfamily 1, group I, member 3 [Homo sapiens]
External ID: CAR558
Protocol: Please refer to other AIDs 1224838 and 1224837 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the CAR antagonist mode assay (AID 1224838) and cell viability counter screen (AID 1224837). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Activity SummaryAntagonist ActivityAntagonist Potency (uM)Antagonist Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active antagonistactive antagonist0.029849295-112.5989031active antagonist0.161535287-92.43221464Selleck
active antagonistactive antagonist0.039048175-114.2426168active antagonist0.219584025-47.7170068GVK
active antagonistactive antagonist0.201283251-139.5018201active antagonist1.424976291-88.48009673SigmaAldrich
active antagonistactive antagonist0.138548153-128.784838active antagonist3.101706799-63.14155548Bosche
active antagonistactive antagonist0.174421791-123.4441969active antagonist4.057582967-89.67194345Microsource
active antagonistactive antagonist0.026603212-97.41352858active antagonist0.087417975-61.2803848GVK
active antagonistactive antagonist0.449702266-142.1196017active antagonist1.722893406-89.63292438Sigma DiscoveryCPR
active antagonistactive antagonist0.069438566-98.57429404active agonist21.95840253944.4990598Prestwick
active antagonistactive antagonist0.400797566-127.8309906active antagonist1.722893406-86.40756542SIGMA
active antagonistactive antagonist0.246377329-118.072959active antagonist3.90481751-60.4793801Tocris
active antagonistactive antagonist0.31017068-117.4079348active antagonist2.560161774-88.85223199Sequoia
active antagonistactive antagonist0.643083562-131.5734854active antagonist5.731488281-92.60138254Sequoia
active antagonistactive antagonist0.032230527-79.19766633active antagonist0.101921876-39.51345173Tocris
active antagonistactive antagonist0.083098224-89.92277055active antagonist0.485577337-67.3587307Astellas Pharma
active antagonistactive antagonist0.286341893-109.4100987active antagonist0.940917528-59.06750299SIGMA
active antagonistactive antagonist0.04216325-77.88711502inactive0Prestwick
active antagonistactive antagonist0.88451444-131.0330354active antagonist3.261156149-110.0738208Spectrum Chemical
active antagonistactive antagonist0.166814946-96.87831543active antagonist6.269529643-115.9567276LKT Lab
active antagonistactive antagonist0.118832183-90.03043134active antagonist3.101706799-59.80740604SIGMA
active antagonistactive antagonist0.343762429-105.7315439active antagonist66.0072656-37.72360778LightBiologicals
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV292
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-4.31012.72020.9178130.50640 0 0 0 0 0 0 0 0 0 0 0 0 0 010.20720.11691.0877-0.82831.40810.2240.44220.76721.39391.5438-0.52370.24463.980310.2072QC'd by LightBiologicals0
Inactive04-1.00310.455-0.67910.1097-0.0294-0.3209-0.37240.3015-2.9009-0.9527-0.64320.03660.1488-1.0031QC'd by LightBiologicals0
Inactive04-9.16830.0869-0.6701-0.08740.2948-0.4295-0.4940.2003-0.30420.2523-3.3942-5.4731-5.7204-9.1683QC'd by Acros0
Inactive0-4.31013.51170.9507-25.0034-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.8362-0.4896-1.99840.3098-1.4204-1.1063-1.5973-2.1128-1.7691-0.4168-3.97930.2084-7.1505-20.8362QC'd by SIGMA0
Inactive0-4.71011.41630.9233-16.3759-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.06320.58450.4616-0.06850.1124-0.0471-0.6224-0.7456-3.1099-1.0709-2.8889-7.0663-11.7943-14.0632QC'd by TCI0
Inactive04-0.1154-0.97120.01120.59710.47560.9356-0.6754-0.2241-0.0015-0.2312-0.8380.08420.3198-0.1154QC'd by SIGMA0
Inactive042.90551.4095-0.52852.56062.61722.3687-0.11732.0740.9379-0.23222.14080.43640.55052.9055QC'd by SIGMA0
Inactive040.4365-2.4513-0.0327-0.14261.6133-0.5704-1.3037-0.4536-0.8740.3518-1.20130.9376-1.70620.4365QC'd by Enamine0
Inactive04-0.4372-0.38510.8434-0.56520.5908-0.8441.5676-0.49420.14072.735-0.92472.0890.0301-0.4372QC'd by Astellas Pharma0
Inactive040.2805-0.57020.08670.190.13910.7228-0.40230.5939-0.08271.22771.56540.84720.1071-0.09450.2805QC'd by SIGMA0
Cytotoxic13.8006104.659882Complete curve; high efficacy-4.86011.50950.9746-106.1752-1.5154-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.0220.44760.6282-0.51490.5417-0.18921.52460.7998-10.1237-19.7042-19.2339-57.3648-93.6289-93.022QC'd by LightBiologicals0
Inactive04-0.39550.69810-3.06970.47780.4618-1.9546-1.961-1.23861.8886-1.5214-1.116-4.356-0.3955QC'd by SIGMA0
Inactive041.64271.72030.0899-0.02840.55570.76330.37690.7462-0.11642.84762.2382.29760.06821.6427QC'd by SIGMA0
Cytotoxic54.947737.36420Single point of activity-4.26013.67720.955-38.364-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.3034-0.2157-0.2184-0.94891.6034-0.1225-0.1335-1.1928-0.5138-0.4285-1.2985-6.4623-5.9048-30.3034QC'd by SIGMA0
Inactive04-2.6646-0.61930.7292-0.0404-0.8078-0.162-0.5396-1.2322-3.6502-2.93792.9929-2.3902-4.2836-2.6646QC'd by SIGMA0
Inactive04-0.1215-0.22550.433-0.2813-0.5615-0.3215-0.6703-1.9336-2.5044-0.0953-0.5624-1.2739-0.3684-0.1215QC'd by FLUKA0
Inactive04-0.4775-1.05130.15671.3131-0.7122-1.1962-0.9485-0.0481-2.22321.37960.04690.6934-2.729-0.4775QC'd by SIGMA0
Inactive042.5338-0.1122-0.54020.52120.06360.0597-0.09260.1726-0.30530.89490.6631-0.32610.8712.5338QC'd by SIGMA0
Inactive0-4.31013.990.9457-19.4313-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.6094-0.0324-2.4557-2.2868-0.0647-0.7762-0.724-0.8002-1.03751.38830.8393-0.3638-3.9235-16.6094QC'd by SIGMA0
Inactive04-2.3612-0.93230.606-0.64620.11111.8175-0.12220.08420.31443.2040.06781.7962-1.3361-2.3612QC'd by SIGMA0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:15218 靶标:N/A
External ID: ES_Opera
Protocol: To perform high content microscopy screening, HeLa cells with stable expression of F508del-CFTR were cultured in 96-well PE ViewPlates (Perkin Elmer, Waltham, MA) for one day prior to well by well addition of two thousand known bioactive compounds from the NIH Roadmap Molecular Libraries Small Molecule Repository. Ten mM DMSO stocks of compounds were diluted 500-fold in growth medium, then added in equal volume to assay plates to yield a final screening concentration of 10 M.
After a 24h treatment period, cells were fixed, permeabilized, and labeled with 3G11 antibody, which recognizes intracellular CFTR epitopes in NBD1, then visualized with AlexaFluor488 anti-mouse conjugate and DRAQ5 fluorescent DNA label (Axxora, Farmingdale, NY). Nine microscopic fields per sample well were then imaged using the Evotec Operatrade mark QEHS automated confocal microscope equipped with a 20x magnification Olympus objective lens (Perkin Elmer). Automated analysis of the resulting images was performed using Acapellatrade mark (Perkin Elmer) software as follows. High contrast labeling of cellular nuclei by DRAQ5 enabled rapid image segmentation by intensity threshold. Corresponding cytoplasm and cell margins associated with each nucleus were subsequently defined by image threshold of lower contrast cytoplasmic / RNA staining of DRAQ5. Further segmentation of images into regions of interest for analysis included plasma membrane (a 2 pixel wide region corresponding to cell margin) and perinuclear region (a 5 pixel wide region encircling the outside of the nuclear mask). Three criteria were used to track expression and subcellular localization of: 1) F508del-CFTR signal in the region of interest, designated as the plasma membrane (PM); 2) F508del-CFTR signal in the perinuclear region of the cell, as a proxy for the ER; and 3) fluorescence signal across the entire cell (Total) to monitor total F508del-CFTR protein. Each measurement was expressed as the mean fluorescent intensity for all cells imaged in 9 microscopic fields per sample.
Comment:
PM_IntensityTotal_IntensityTested_Concentration
808610
788810
11013410
727810
909210
9610210
909610
9910610
717710
869010
949410
838810
929610
929210
858510
9911410
909410
728010
889110
939710
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:HNF4 Alpha
External ID: BHood-p-21Jun2013-01
Protocol: This assay is to identify inhibitors of HNF4 alpha protein binding to DNA
##

A. Materials:##
Description#Company#Cat #
1M TRIS #BioRad#161-0719
DTT#RPI#D11000
Glycerol#Amersco #0854-1L
NaCL#Fisher Bioreagents#BP358-212
Tween 20#Sigma#P1379
HNF4 Protein #Assay Provider#
FITC-DNA#Assay Provider#
1536 well black high base plate#Aurora#00019120BX
##
B. Plate Map:##
Positive control in columns 1 and 2 is DNA and 70nM Protein##
Negative control in columns 3 and 4, Protein at 650nM and DNA, DMSO##
Test compound in columns 5 - 48, Protein at 70nM + DNA + test compound

C. Procedures:##########
Step#Description#########
1#Transfer test compounds to columns 5-48, DMSO to columns 1-4 using ECHO 555.#########
2#Set up Envision as as described in G. Instrument setting.#########
3#Prepare assay buffer.#########
4#Dispense undiluted HNF4 protein solution at into col 3-4 and 140nM HNF4 protein into columns 1,2, and 5-48. #########
5#Dispense 3uL/well of FITC-DNA (FAC = 5nM) using BioRAPTR#########
6#Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute.#########
7#Incubate plates at RT for 1 hour.#########
8#Read using FP protocol on Envision#########
##########
D. Assay Conditions:##########
Reagent##Final Conc.#Unit#######
1#Tris pH7.4#0.02#M#######
2#NaCl#0.05#M#######
3#DTT#0.01#M#######
4#Glycerol#10#%#######
5#Protein#650 for EC100 and 70nM for EC20#uM#######
6#DNA#5#nM#######
*#6uL reaction volume#########
*#60 min reaction at room temp#########
*#10uM test compound#########
*#0.5% DMSO
Comment:
%Activity_Corrected at 10 uMValue at 10 uMMean HighSTD Deviation HighMean LowSTD Deviation Low
-6.39105.0999985116.057.38199.696.53
-0.54109.8000031116.057.38199.696.53
-0.14111.9000015116.057.38199.696.53
3.17114.4000015116.057.38199.696.53
0.67110.0999985116.057.38199.696.53
-1.92108.3000031116.057.38199.696.53
-1.35108.0999985116.057.38199.696.53
1.56110.5999985116.057.38199.696.53
1.88112.1999969116.057.38199.696.53
1.69111.5999985116.057.38199.696.53
-0.73109.9000015116.057.38199.696.53
-0.36111.1999969116.057.38199.696.53
9.41119.5999985116.057.38199.696.53
-0.85109.3000031116.057.38199.696.53
-0.03110.0999985116.057.38199.696.53
2.36112116.057.38199.696.53
3.01113.1999969116.057.38199.696.53
-0.42109.0999985116.057.38199.696.53
-1.98107.5999985116.057.38199.696.53
0.83108.9000015116.057.38199.696.53
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV261
Protocol: Tox21 Assay Protocol Summary:

The mixture of HepG2 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-0.26620.67031.4763-7.86010.62961.6439-0.485110.60941.2638-0.77391.2431-0.534713.4202-0.2662QC'd by SigmaAldrich0
Cytotoxic31.2778102.254240Partial curve; high efficacy-4.50482.25260.968-103.8742-1.62-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-90.6406-2.95951.25795.559-9.0576-2.3901-8.7951-2.9108-3.27020.8382-3.4053-9.3391-64.5158-90.6406QC'd by Sensient0
Cytotoxic10.931394.762982Complete curve; high efficacy-4.96133.06540.9629-95.2905-0.5276-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-87.7395-1.27940.67685.0387-3.7769-0.1919-0.1178-1.6869-4.2628-2.6139-3.114-87.8216-90.2372-87.7395QC'd by Io-li-tec0
Inactive0004-2.41291.3956-4.16373.5243-5.8685-1.01070.51760.1618-4.9932-1.0057-1.2821-7.4184-5.5068-2.4129QC'd by SIGMA0
Cytotoxic35.40992.769440Partial curve; high efficacy-4.45092.33320.9808-91.15061.6187-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-77.38681.09870.239611.4258-0.50932.3570.5258-1.95311.68720.28711.9844-9.716-46.1242-77.3868QC'd by Io-li-tec0
Inactive0-7.50970.30.5207-3.81855.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.9173.66120.12352.2133-0.8421.10190.9559-1.6737-0.1244-3.1217-2.039-6.93210.8766-2.917QC'd by SIGMA0
Inactive00042.27361.34564.39256.24761.83614.5650.6623.17661.92281.67570.95962.41711.75032.2736QC'd by SIGMA0
Inactive0-6.96134.95490.4857-2.0409340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.11740.89896.65672.81771.334.05530.0163-5.219-1.87890.2926-0.0570.4195-2.2-7.1174QC'd by SIGMA0
Inactive0-4.70014.95490.5914-15.9637-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.9613-4.1830.41095.569-1.66683.59060.2077-3.2723-1.38830.16930.2608-3.8346-14.9697-2.9613QC'd by SIGMA0
Inactive0004-2.3622-1.9219-0.34070.2774-0.4936-0.478-0.2306-1.8006-2.55650.0517-2.204-2.8226-6.1715-2.3622QC'd by SIGMA0
Inactive0-4.26964.95490.8419-27.0571-240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-22.9643-1.66630.02590.308-4.1056-8.1214-0.0418-5.5982-0.4306-0.8456-1.5064-1.6208-3.9632-22.9643QC'd by SIGMA0
Inactive0004-1.6236-0.746-2.39663.4819-4.7806-0.1932-1.6365-5.8763-1.47840.01-6.9774-0.07040.0356-1.6236QC'd by SIGMA0
Inactive00040.7707-3.27651.3611.555-0.1221-0.3791.1184-2.0405-0.63510.218-4.9126-6.1749-0.3660.7707QC'd by SIGMA0
Inactive00042.5308-1.9447-2.24992.66670.06382.30611.48490.1054-2.817-0.6612-2.8286-5.24455.13872.5308QC'd by SigmaAldrich0
Inactive00040.3151-0.1759-6.8242.3532-2.5273-0.0411.77952.35540.1109-7.2061-2.8467-6.05672.3370.3151QC'd by SIGMA0
Inactive0-4.66184.95490.471210-2.596140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.1799-3.424-2.9862-0.6424-3.6038-3.1177-1.9168.0763-3.7778-5.8514-4.0513-3.577310.8157-1.1799QC'd by SIGMA0
Inactive0004-5.9223-6.2685-3.7694-1.61-7.6686-4.6601-1.27066.9517-1.775-3.8643-5.3257-4.44672.4221-5.9223QC'd by SigmaAldrich0
Inactive0004-4.029-2.29010.632725.6927-3.2026-3.0528-1.48314.15260.8397-2.6293-3.2865-1.796615.5972-4.029QC'd by Io-li-tec0
Inactive0-7.64790.30.57453-8.730640 0 0 0 0 0 0 0 0 0 0 0 0 0 01.52-5.5283-5.9036-1.2224-4.2271-1.55110.8611.371-2.04390.27432.471-0.70294.9081.52QC'd by SIGMA0
Inactive0004-0.24473.46312.74895.92733.97262.71541.23241.88212.87492.86910.75010.8324-1.1026-0.2447QC'd by SigmaAldrich0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV775
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive04-0.96590.8898-4.8159-4.8051-10.85392.00630.2658-3.4476-3.5183-4.60534.276-0.2087-4.0597-0.9659QC'd by ChemService0
Activator22.68377.500310Single point of activity-4.64434.95490.899578.921.419730 0 0 0 0 0 0 0 0 0 0 0 0 0 128.23131.0977-2.20470.21540.57129.35350.12394.7513-4.071613.57114.13074.155782.527728.2313QC'd by Alfa Aesar0
Inactive0-8.79692.40640.70060.50351840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.84039.82273.6174-2.9137-1.116-0.04373.65163.39430.6174-1.2787-0.46133.71932.1743-2.8403QC'd by SIGMA0
Inactive0-7.96354.95490.3891-3.02169.540 0 0 0 0 0 0 0 0 0 0 0 0 0 112.70322.890922.51063.3877-7.68681.3786-3.89096.7609-5.6448-8.5965-8.816-2.24533.572912.7032QC'd by SIGMA0
Inactive04-7.5796-6.7661.04820.597159.63963.81297.15211.4315.94461.46332.5613-0.2268-9.7763-7.5796QC'd by SigmaAldrich0
Inactive04-0.55682.99589.14274.796.269-1.11660.9079-0.585215.42052.85479.924113.83452.6138-0.5568QC'd by SigmaAldrich0
Inactive0-4.96744.95490.34836.5-4.520140 0 0 0 0 0 0 0 0 0 0 0 0 0 010.5242-3.6931-0.2524-8.4996-11.50323.1295-2.48742.0546-5.6624-8.1819-12.51138.43910.713210.5242QC'd by ChemService0
Inactive0420.790748.63253.30592.09523.51677.0478-0.132413.46681.409410.74818.92113.8-0.12720.7907QC'd by SIGMA0
Inactive0-4.8524.95490.5238-10.35554.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-7.57912.2632-2.22510.158212.07365.32462.9693.94422.435319.18123.8473-3.6889-13.2129-7.5791QC'd by SIGMA0
Inactive040.85620.9645-3.5889-6.6697-0.2872-18.1507-0.3668-0.2892-14.71464.854513.73898.332-6.90480.8562QC'd by SIGMA0
Inactive0-5.87274.95490.37767.5-4.091640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.1552-3.9611-10.38332.6661-8.960.1820.26360.4745-5.795621.96346.0559-2.48545.2743-7.1552QC'd by SIGMA0
Inactive0-4.56444.95490.506-15.76975.540 0 0 0 1 0 0 0 0 0 0 0 0 0 0-14.8081-4.570811.00963.369864.7731-2.1070.999212.957810.16817.088213.26596.132-11.628-14.8081QC'd by SigmaAldrich0
Inactive04-3.2157-5.7722-7.396213.7068-0.731-5.3098-0.270911.3982-1.62083.9786-12.3964-9.555-1.1499-3.2157QC'd by SIGMA0
Inactive0-7.25934.95490.32-6.12140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.7215-4.4043-1.546713.9538-0.1176-2.2902-7.2216-8.1463-3.6229-4.6362-10.1-8.0031-6.611-2.7215QC'd by SIGMA0
Inactive04-4.39-6.4733-0.408524.1053-4.3893-9.8384-3.13613.477-3.2614-7.9234-10.35339.4605-3.1213-4.39QC'd by SIGMA0
Inactive040.7154-2.805716.6851-6.8951-1.42365.78640.5672-2.57540.357-0.8413-0.0373-0.2343-2.41890.7154QC'd by SIGMA0
Inactive0-7.91083.1320.32694-6.391140 0 0 0 0 0 0 0 0 0 0 0 0 0 05.1373-3.1578-13.24260.37320.71293.87065.6246.08533.058-0.3775-0.69230.424616.27635.1373QC'd by City Chemical0
Inactive0-4.36143.51170.6129-30.525.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-25.87477.310911.1854.75950.721.86111.188923.82980.9363-5.034812.54485.3932-6.344-25.8747QC'd by Sensient0
Inactive0418.96081.66133.767-0.99175.7941-1.7954-0.53653.42689.26066.3378-0.4530.53757.376218.9608QC'd by SIGMA0
Inactive043.573315.28766.21377.7355-1.7164.0531-4.721445.2796-6.5581-9.994412.3176-6.02470.1453.5733QC'd by SIGMA0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV408
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive048.53831.49545.51920.79227.009-0.8478-0.03192.28538.8413-4.3787-3.13581.45057.65388.5383QC'd by ACC0
Inactive040.49651.0548-0.31072.1965.22131.8741-1.0574-11.3835-0.034615.49621.23434.7392-0.03050.4965QC'd by ACC0
Cytotoxic16.930137.055920Partial curve; partial efficacy; poor fit-4.77132.72020.7119-30.05317.0028-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.2896-4.00955.44459.1825.66294.06920.63465.94055.89723.76626.44865.7617-12.7125-26.2896QC'd by ACC0
Inactive042.29623.0087-1.99717.18371.73190.52393.82442.269810.106-1.31745.0870.692715.7782.2962QC'd by ACC0
Inactive04-14.63-1.5501-9.9374-3.0134-4.4328-2.88331.1197-5.299813.52320-2.76717.1454-1.0799-14.63QC'd by RTI0
Inactive04-6.02471.2321-0.0859-5.3557-13.39742.28822.2565-8.7707-0.1147-6.1694-8.39860.084-6.288-6.0247QC'd by RTI0
Inactive04-3.7135-3.2997-3.7414-5.8868-12.6672-0.8641-1.4917-1.2248-1.4817-2.8215-6.8492-0.4051-4.8669-3.7135QC'd by RTI0
Inactive04-8.9464-8.8617-2.3423-3.563-4.9878-0.3168-0.9864-0.91598.5284-3.3714-12.73545.6937-14.4798-8.9464QC'd by RTI0
Inactive04-8.4909-8.35940.032-7.8769-10.3346-5.7828-3.1047-5.4735.5521-2.1139-3.8009-4.4179-12.9761-8.4909QC'd by RTI0
Cytotoxic56.06946.408121Partial curve; partial efficacy-4.25131.96730.7233-49.073-2.6649-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.5901-1.6294-3.9715-5.215-5.8802-3.0995-0.1987-9.346-0.8796.1445-9.4957-7.4789-15.6045-36.5901QC'd by RTI0
Cytotoxic53.085353.600821Partial curve; partial efficacy-4.2752.40640.7206-53.47040.1304-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-43.4173-1.1372-5.349-1.8973-0.4342-4.2881-0.76361.7769-4.206125.2788-4.97-1.434-22.046-43.4173QC'd by RTI0
Cytotoxic2.292672.807784Complete curve; high efficacy-5.63972.25260.9747-75.9817-3.174-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.1161-3.65840.3853-1.3871-0.3670.3574-4.8789-7.5102-15.117-57.7466-70.3156-62.3401-81.3546-81.1161QC'd by RTI0
Cytotoxic55.3956102.03141Partial curve; high efficacy-4.25651.86170.9254-104.6061-2.5751-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-79.2471-0.5886-6.1071-1.737-7.6263-2.1359-1.2977-2.4911-1.08084.9562-9.0768-20.2884-31.0764-79.2471QC'd by RTI0
Inactive04-11.9507-4.1317-10.3768-0.0871-1.5726-9.60140.0652-4.8723-1.2808-4.8418-12.8806-5.353-16.723-11.9507QC'd by RTI0
Cytotoxic31.633361.190340Partial curve; high efficacy-4.49991.96730.8483-62.9529-1.7627-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.7891-1.2215-1.8895-3.6905-1.78120.7209-2.316-8.3802-1.19224.8583-15.6308-13.4062-36.5957-62.7891QC'd by RTI0
Cytotoxic24.71783.579740Partial curve; high efficacy-4.6071.210.9158-86.3028-2.7231-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-71.919-1.6524-0.2823-0.7682-13.767-4.1612-2.1857-1.60340.1285-8.3122-29.8628-20.29-59.8611-71.919QC'd by RTI0
Cytotoxic39.910848.969820Partial curve; partial efficacy-4.39893.1320.7479-46.6912.2787-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-42.8915-1.4724-1.71352.4136-2.42740.6336-1.32852.9565-3.098910.9402-0.76438.9975-21.9495-42.8915QC'd by RTI0
Inactive0-4.19191.3310.6301-38.9316-5.899440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1097-2.9424-8.939-1.5828-14.107-1.7509-3.9946-12.5941-2.2873-4.1107-8.573-9.327-13.3946-29.1097QC'd by RTI0
Inactive0-5.34142.40640.6908-18.919-340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.2635-2.2657-6.0647-2.6148-8.7621-1.4868-5.6785-0.6261-3.5564-1.2527-17.2384-15.5057-20.3492-18.2635QC'd by RTI0
Cytotoxic30.876338.512720Partial curve; partial efficacy-4.51041.3310.8258-41.1094-2.5967-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-38.0642-4.06730.1117-1.7013-2.9403-0.6733-4.992-1.4145-5.0534-2.0416-19.1431-6.8148-21.1762-38.0642QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV344
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.67134.95490.6549101.284940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.146800.02513.4553-2.26260.26950.44014.0318-0.2863.12986.637112.25044.6241-0.1468QC'd by ACC0
Inactive04-2.605600.38062.6444-0.8901-12.6394-1.3087-3.0560.3820.55453.4646-0.01940.3046-2.6056QC'd by ACC0
Activator18.9959300.141843Partial curve; high efficacy-4.72131.34430.9737302.97472.83292.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0233.776804.7574-0.75475.09110.96012.96235.13960.23320.796128.169383.5125111.6322233.7768QC'd by ACC0
Inactive043.748203.79591.4793.6038-3.2820.11971.4384-0.41570.297810.8637-0.76562.38743.7482QC'd by ACC0
Inactive04-4.96040-4.9633-1.4044-6.0069-2.4696-0.2144-5.30882.3858-9.7548-0.02541.7914-4.0632-4.9604QC'd by RTI0
Inactive04-1.54146.9276-3.29011.7218-1.45891.4621.2447-0.18510.41510.85143.1833-0.1838-4.7946-1.5414QC'd by RTI0
Inactive045.371900.802-4.4806-7.7141-8.7492.6447-4.0542-8.1541-4.99260.73110.1613-4.95695.3719QC'd by RTI0
Inactive04-0.19640-1.1762-1.43460.794-0.2279-1.25663.72962.4954-1.6049-2.622730.7271-3.9862-0.1964QC'd by RTI0
Inactive040.2002-1.6382-1.639512.97330.2813-0.6075-3.66799.9906-3.9057-5.007611.250917.5257-3.76090.2002QC'd by RTI0
Inactive04-10.7760-1.374-16.3867-9.6856-8.8335-8.12680.3586-11.6288-17.550.2134-14.9266-0.4043-10.776QC'd by RTI0
Inactive043.52360-8.06310.119-3.62550.551.2328-4.3353-4.8215-9.46151.31690.7882-4.48953.5236QC'd by RTI0
Inactive04-5.2402-1.631-3.7223-4.049820.9396-4.15646.27670.17740.51692.94763.51113.9943-4.4898-5.2402QC'd by RTI0
Inactive040.13350-0.5332-1.0415-2.76140.94731.12528.07280.1983.19610.038410.1274-1.26910.1335QC'd by RTI0
Inactive042.485905.4776-3.2287-2.492411.30651.29642.79110.3823-0.682512.9564-3.23979.43392.4859QC'd by RTI0
Inactive04-1.052900.14737.26823.4216-0.63920.5348-0.2158-0.82884.36890.46485.01514.0525-1.0529QC'd by RTI0
Inactive048.21080-7.41464.402-3.1366-6.0671-1.21010.24475.5959-5.8949-0.53856.2219-3.00048.2108QC'd by RTI0
Inactive04-12.68710-2.66038.1036-7.2889-2.27283.1657-4.8527-7.9749-5.6664-4.77134.9243-15.3033-12.6871QC'd by RTI0
Inactive047.19110-0.0979-2.0844-0.50311.08660.34060.0709-2.1912-0.489112.82370.7893-4.00177.1911QC'd by RTI0
Inactive04-6.318500.8187-0.30319.563-2.5783-1.9705-5.1937-6.3994-1.1616-0.399913.6198-1.1282-6.3185QC'd by RTI0
Inactive0-4.71044.95490.3797.5-0.152240 0 0 0 0 0 0 0 0 0 0 0 0 0 06.03202.3589-0.0405-2.23747.1608-4.6574.1838-3.6711-3.59410.20892.01118.88176.032QC'd by RTI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV608
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-7.91014.95490.36573-4.566540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.497-5.0447-3.1586-2.492211.97450.72283.8462-0.90310.08594.51117.45240.57260.4752-0.497QC'd by LightBiologicals0
Inactive04-4.40016.1277.37653.9732-17.7212-2.1112.9369-2.0138-1.9612-1.764212.23195.3628-2.13280.098QC'd by Acros0
Inactive0-8.21014.95490.33563-1.749140 0 0 0 0 0 0 0 0 0 0 0 0 0 05.5634-1.3307-1.40184.77328.77114.95594.6943-0.7381.5956-0.0592.190.34873.49635.5634QC'd by SIGMA0
Inactive043.70551.17292.93790-0.2228-9.54881.8978-8.10749.541118.06111.6453.6969-1.03733.7055QC'd by LightBiologicals0
Cytotoxic4.896688.376283Complete curve; high efficacy-5.31014.95490.9452-85.76822.608-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.830512.8268-2.6197-8.3186-5.4755-9.2803-1.9474-5.55969.722513.1194-75.9591-88.787-83.6145-81.8305QC'd by LightBiologicals0
Inactive042.15842.0535-7.6545-2.11364.08342.3865-8.52680.2892.7267-18.22342.29387.61751.43972.1584QC'd by SIGMA0
Inactive04-5.3937-4.1455-3.6603-2.2052-4.3322-6.56930.65963.8239-4.3499-2.6615-10.2378-9.0990.1562-5.3937QC'd by TCI0
Cytotoxic54.947737.847820Single point of activity-4.26013.92950.8286-41.3478-3.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2065-2.8063-1.0619-1.1535-11.1607-6.2004-0.9737-6.3091-4.9069-5.5424-0.04442.153-9.6829-33.2065QC'd by SIGMA0
Cytotoxic24.541244.873220Partial curve; partial efficacy; poor fit-4.61010.50.6308-39.87325-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.2718-0.56162.411714.059315.66811.1581.1836-0.6512-6.5098-16.0797-3.6424-3.6892-20.0211-31.2718QC'd by LightBiologicals0
Cytotoxic34.669736.874120Partial curve; partial efficacy-4.46012.40640.6776-36.19650.6776-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.72842.6457-1.8233-1.25981.7444.9434-5.9651-5.9564-3.446717.4959-3.98991.7512-20.3635-30.7284QC'd by SIGMA0
Inactive0-4.81014.95490.4769-11.6033140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-10.84660.72163.79-3.66135.31625.6131-11.26978.4546-1.82790.64852.3612-4.8275-12.5861-10.8466QC'd by TCI0
Inactive04-15.3343-6.1477-2.54385.61752.0543-8.60916.70164.2089-9.88019.3124-0.79122.42880.8877-15.3343QC'd by SIGMA0
Inactive0-4.57134.95490.3813-15.743-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.95255.2776-9.68751.75232.8732-8.9944-2.1822.7189-0.312-0.3041-2.72720.1017-0.3966-13.9525QC'd by SIGMA0
Inactive0-4.46012.33320.4405-16.6993-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3328-5.4711-1.2162.40880.06260.6089-10.5794-1.90030.58163.5724-1.7139-0.299-10.3989-14.3328QC'd by SIGMA0
Inactive041.3535-3.8080.7096-11.63583.602-1.64566.4772-2.12450.203-1.5066-0.24212.6085-12.46621.3535QC'd by SIGMA0
Inactive0-5.61011.88510.3104-10.1584-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.0046-1.67529.2353-10.96540.3332-1.3167.45820.1397-3.1021-9.4311-9.9917-7.9985-9.7243-2.0046QC'd by SIGMA0
Inactive043.5237-0.2824-0.7839-2.5676-13.10910.26537.76231.1115-7.6587-1.128810.7227-9.6473-12.14623.5237QC'd by SIGMA0
Inactive04-15.2694-0.43230.0711-7.7901-19.56841.5675.88014.11291.37130.8506-0.3304-9.2389-7.9287-15.2694QC'd by SIGMA0
Inactive040.5651-0.08312.2526-8.22182.5641-0.7189-11.0158-10.5852-0.5531-0.0079-0.51660.7582-0.29270.5651QC'd by SIGMA0
Inactive040.2096-3.79912.39421.9929-4.0354-4.7863-3.0068-1.183-0.60184.805-3.8894-4.77883.39830.2096QC'd by Crescent0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV871
Protocol: Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The fluorescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0-5.36284.0450.627912.5-4.220640 0 0 0 0 0 0 0 0 0 0 0 0 0 018.47374.785-13.5172-7.54910.0834-3.0682-8.4784-4.9706-8.4795-0.440510.08988.83129.2318.4737QC'd by Acros0
Inactive04-1.9726-0.11323.32121.22842.22955.24943.331695.41563.5989-0.39819.1852.3425-0.0425-1.9726QC'd by SigmaAldrich0
Inactive040.52996.565330.86130.0537-0.7973-1.4576-19.67440.91642.18472.45347.0024-0.11537.23450.5299QC'd by SigmaAldrich0
Inactive041.391-3.65930.68671.8583-0.98851.22450.5827.4453-0.811-0.7282-2.21231.53941.2161.391QC'd by SigmaAldrich0
Inactive04-7.1974-8.4109-1.2726-1.79213.4951-10.30145.42160.82013.9626-2.9581-9.5234-9.3211-1.8539-7.1974QC'd by SIGMAInactive0
Inactive0-4.41980.80.4465281.824340 0 0 0 0 0 0 0 0 0 0 0 0 0 020.86274.6075-6.39644.39716.08923.06696.9371-3.23310.19180.478220.98163.894711.439720.8627QC'd by SigmaAldrich0
Inactive04-0.33952.0069-4.2373-2.8916-5.9532-0.28180.8383-6.1704-2.812810.3448-4.04368.735-14.0751-0.3395QC'd by SIGMA0
Inactive0-5.85514.95490.483-4.505140 0 0 1 0 0 0 0 0 0 0 0 0 0 02.0744-4.2005-3.962729.512-6.2924-5.41930.8402-2.6632-5.77644.31356.5313-3.7056.1162.0744QC'd by SigmaAldrich0
Inactive04-7.7148-8.6379-10.648-4.5465-7.744626.3762-4.7602-5.8488-7.4385-0.6879-10.2208-9.9089-11.0287-7.7148QC'd by SIGMA0
Inactive04-0.12112.173-3.07059.1166-2.33451.309311.83099.59139.8485-4.1414-5.80172.46060.1159-0.1211QC'd by ChemService0
Inactive042.092-5.28165.51692.8221-7.8621-1.9177-11.3254-0.099110.23477.6035-12.36499.8876-2.22032.092QC'd by SIGMA0
Inactive0-8.92124.95490.5882-3.64312640 0 0 0 0 0 0 0 0 0 0 0 0 0 116.4515.72440.39761.5304-9.9726-6.6007-13.4526-8.87650.63250.67310.55321.552-4.450916.451QC'd by Alfa Aesar0
Activator39.052343.46110Partial curve; partial efficacy; poor fit-4.40842.33320.751545.94322.48232.40 0 0 1 0 0 0 0 0 0 0 0 0 0 038.37345.23070.829531.07040.1687-4.7562-0.46510.043412.29261.9435-6.03166.852121.30738.3734QC'd by SigmaAldrich0
Inactive0-4.21064.95490.398520-1.688840 0 0 0 0 0 0 0 0 0 0 0 0 0 014.7209-0.0803-6.3678-0.75280.98711.47160.7125-3.4369-6.5823-9.1506-1.42128.8678-2.769914.7209QC'd by SigmaAldrich0
Inactive04-2.7778-1.827112.03650.486-2.5629-1.32513.7253-1.5180.3141.176645.90230.159811.0085-2.7778QC'd by SIGMA0
Inactive0-4.26094.95490.591724-1.751640 0 0 0 0 0 0 0 0 0 0 0 0 0 019.9111.6759-10.62630.55233.4949-5.45712.066-7.00591.6721-8.6743-5.844-0.22360.375519.911QC'd by SIGMA0
Inactive0-4.30084.50450.320215-3.037140 0 0 0 0 0 0 0 0 0 0 0 0 0 012.9456-8.36016.4423-2.069-13.7809-10.43173.9243-4.66772.45021.7781-7.6678-3.8988-0.089212.9456QC'd by SIGMA0
Inactive040.7355-2.92450.42062.0802-1.8154-1.0289-10.936112.75536.816816.4481-3.0064-1.7775-4.05830.7355QC'd by SigmaAldrich0
Activator61.252864.01810Single point of activity-4.21294.95490.858161.2934-2.724630 0 0 0 0 0 0 0 0 0 0 0 0 0 051.34732.2111.28723.44490.9419-0.4027-6.4574-10.2539-4.3072-5.20792.7037-10.1244-7.798751.3473QC'd by NTP-MRI Repository0
Activator19.236547.54910Partial curve; partial efficacy; poor fit-4.71590.60.649539.3953-8.15372.40 0 0 0 0 0 0 0 0 0 0 0 0 0 033.1538-9.3416-13.6082-8.1127-1.6253-7.819-5.6875-0.00342.0428-4.0001-1.123132.22463.604233.1538QC'd by SIGMA0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: RTV234
Protocol: Tox21 Assay Protocol Summary:

The mixture of Hek293 cell suspension and reagents were dispensed at 600cells/6 ul/well in 1536-well tissue culture treated black solid bottom plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 5 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls was transferred to the assay plate by a pintool work station. The plates were incubated at 37 C for 40 hours. The luminescence intensity were measured at 0h, 8h, 16h, 24h, 32h and 40h time points using ViewLux plate reader during compound treatment.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000049913 uM-Replicate_1Activity at 0.0000114526 uM-Replicate_1Activity at 0.0000453222 uM-Replicate_1Activity at 0.0001077752 uM-Replicate_1Activity at 0.0002496487 uM-Replicate_1Activity at 0.0005152588 uM-Replicate_1Activity at 0.00141 uM-Replicate_1Activity at 0.00434 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.290 uM-Replicate_1Activity at 0.887 uM-Replicate_1Activity at 2.716 uM-Replicate_1Activity at 6.973 uM-Replicate_1Activity at 15.76 uM-Replicate_1Activity at 35.30 uM-Replicate_1Activity at 76.83 uM-Replicate_1Activity at 199.8 uM-Replicate_1Activity at 725.3 uM-Replicate_1Activity at 1537.0 uM-Replicate_1Activity at 3438.0 uM-Replicate_1Activity at 7687.0 uM-Replicate_1Activity at 17190.0 uM-Replicate_1Activity at 38440.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive041.4151.82862.674.4612-21.88945.2891.79690.47535.2674-1.33670.68340.5397-4.33861.415QC'd by SIGMA0
Inactive04-1.02587.11741.27220.51182.55861.64240.31039.1837-0.7145-5.251417.07271.10391.516-1.0258QC'd by SIGMA0
Inactive041.10724.7422-14.65183.03990.81862.12427.8806-0.7861-0.8393-17.7251.032.77213.21491.1072QC'd by SIGMA0
Inactive04-1.2975-7.5156-1.7607-2.8351-2.5195-0.23390.8421-3.2303-4.5145-2.9122-0.2411-5.44651.9282-1.2975QC'd by SIGMA0
Cytotoxic15.484576.647441Partial curve; high efficacy-4.81011.55790.973-73.08863.5588-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-69.65711.27921.82729.16653.67664.12557.7573-0.03230.53654.9054-15.3202-39.0485-50.1925-69.6571QC'd by SIGMA0
Cytotoxic6.916799.299483Complete curve; high efficacy-5.16012.25260.9732-98.19851.1009-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-92.39264.0017-1.5129-1.637415.48763.65390-1.4445-6.1223-14.5346-44.3162-93.8613-94.6036-92.3926QC'd by SIGMA0
Inactive0-4.56014.0950.3931-13.4834.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.31926.1252-2.708-0.2959-1.3051-0.0669-7.65242.481711.175117.295712.26150.9995-7.4307-13.3192QC'd by SIGMA0
Cytotoxic35.545631.877920Partial curve; partial efficacy; poor fit-4.44924.95490.8013-30.87791-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.3982-0.70575.6931-0.576-3.204-0.62092.1022-0.6841-0.1327-2.50775.1195-4.64584.8975-27.3982QC'd by SIGMA0
Cytotoxic54.94159.901241Partial curve; partial efficacy-4.26014.44950.8504-66.7533-6.8521-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-55.7566-7.1185-13.4234-4.8896-1.1647-5.1185-1.1604-8.7057-8.3595-18.6219-8.3806-15.076-11.3619-55.7566QC'd by SIGMA0
Inactive0-4.39220.80.3294-26.6432.466840 0 0 0 0 0 0 0 0 0 0 0 0 0 0-18.8139-2.0107-0.25740.42393.4251-7.37916.7741-2.6501-1.4254-1.3481-3.4305-2.1594-4.8096-10.1867QC'd by ChemService0
Inactive041.4242-1.4117-1.35191.77728.3092.6272-13.5334-0.4738-6.51733.34678.7899-4.06232.55211.4242QC'd by SIGMA0
Cytotoxic54.880541.325820Single point of activity-4.26064.95490.7418-38.09173.234-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.5215-1.68612.22280.04321.5512-0.6678-0.08082.87264.4384.669110.507313.7977-0.067-31.5215QC'd by SIGMA0
Inactive041.63260.6864-0.5199-3.4385-1.32591.1606-4.70912.05746.44931.72642.8149-7.65451.44991.6326QC'd by SIGMA0
Inactive0-7.44012.58840.5121-8.6466640 0 0 0 0 0 0 0 0 0 0 0 0 0 0-13.5639-0.898314.68312.328.43580.5332-1.6707-10.3512-17.381-6.88062.5252.4826-8.5222-10.2589-13.5639QC'd by SIGMA0
Inactive0-4.26014.95490.661-31.8702140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.5585-1.07999.72286.0204-1.02160.18741.5003-8.4832-3.78212.149110.33190.5084-0.7314-26.5585QC'd by SIGMA0
Cytotoxic27.535754.182440Partial curve; partial efficacy-4.56012.33320.9297-59.6606-5.4782-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-62.1465-12.7387-2.9142-0.2396-2.0276-8.8691-4.5533-3.7966-2.8501-3.592-6.8793-19.8387-36.6909-62.1465QC'd by Nippon0
Inactive040.77551.58255.6326-1.3825.8633-0.1179-1.60791.9758-1.17090.22469.31424.80922.79250.7755QC'd by Grinstad0
Cytotoxic61.644846.570420Single point of activity-4.21014.95490.6068-47.9109-1.3405-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.9258-4.5414-4.5799-1.3986-3.98382.7363-0.3517-10.20126.590713.4794-18.2318-1.10860.443-39.9258QC'd by CalBioChem0
Cytotoxic21.313870.229521Partial curve; partial efficacy-4.67131.64360.8386-65.04025.1893-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-48.68233.50889.639510.051213.56761.44221.37372.01138.0885.4761-5.8906-1.1283-21.0708-48.6823QC'd by Synthonix0
Inactive0-4.57770.30.6027-33.7973740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-24.831110.40646.4001-0.32527.77481.7026-3.75131.00710.0634-8.0957-10.04792.303-7.864-16.8582QC'd by SIGMA0